1. Introduction {#s0005}
===============

Molluscs comprise a significant share of seafoods (mussels, squids, clams, octopuses, snails), which were used as a balanced protein resource ([@b1025]). For centuries, the molluscs were provided with extensive range of human resources, such as dyes, shells, ornaments, and currencies, other than their nutritive values ([@b1030], [@b1125]). For example, "Tyrian purple" made from the secretions of hypobranchial gland of marine muricid snails were considered as major economic factors, among the Roman and Phoenician Empires ([@b1025]). Over the past decades, the significance of the marine and estuarine molluscs was greatly extended as alternate resources to traditional fishery, among various locations of the world ([@b1775]). Also, these were found to be the most sought after food in the world, among the coastal populations of developing and underdeveloped countries, like Asia and Africa ([@b1775]). For example, the green mussel *Perna viridis* was reported as an integral part of the local cuisines, along the Arabian coast of Indian sub-continent ([@b0420]). In several ancient cultures, the molluscs were regarded not only as a healthy diet, but also they were featured in a wider range of traditional remedies ([@b1030]). For instance, the internal shells of cephalopod, *Spirula spirula* was the most expensive marine mollusc in the traditional medicine market of the Durban city in South Africa ([@b1030]). Thus, the marine and estuarine habitats were prominently contributed towards the development of prospective therapeutic leads, functional foods, nutraceutical and pharmaceutical preparations. The organisms belonging to the class of *Mollusca* are of special interest, and they were widely distributed in the marine and estuarine ecosystems ([Fig. 1](#f0005){ref-type="fig"} ). A total of seven classes of molluscs were classified, which includes Monoplacophora, Aplacophora, Polyplacophora, Bivalvia, Scaphopoda, Gastropoda, and Cephalopoda based upon their phylogenetic analysis ([@b1025]) (Description S1; Figs. S1-S2). The percentage distributions of prominent groups of marine organisms against molluscs (6 %) were plotted in [Fig. 2](#f0010){ref-type="fig"} .Fig. 1Representative photographs of molluscs (collected from the southwest coastal waters of India) belonging to the classes of gastropods (**A**) *Babylonia spirata* (collected from the harbors of Neendakara, Kerala) cephalopods (**B**) *Uroteuthis (Photololigo) duvaucelii* (collected from the harbors of Thoppumpadi, Kerala), and bivalves (**C**) *Perna viridis* (collected from Elathur, Calicut, Kerala), (**D**) *Paphia malabarica* (collected from the Ashtamudi Lake, Kerala), (**E**) *Crassostrea madrasensis* (collected from the Sathara Island, Cochin, Kerala), (**F**) *Villorita cyprinodes* (collected from the Vembanad Lake, Kerala).Fig. 2Percentage share of molluscs among various classes of marine organisms.

Marine and estuarine ecosystems are extremely complex with wide-ranging pressure limits from 1 to 1000 atm, nutrient limits (oligotrophic or eutrophic), thermal conditions from freezing point in Antarctic to 350 °C in the deep hydrothermal regions ([@b0635]). Chemically or structurally distinctive bio-potent secondary metabolites were originated through their varied biosynthetic mechanisms as a part of their defensive mechanisms to survive against the extreme stress factors in the marine ecosystems ([@b0635]), which could not be found in any terrestrial organisms. These secondary metabolites were regarded as the chemical weapons to withstand in their unfavourable environmental conditions. Although, scattered reports were available to substantiate the health benefits, and therapeutic pluralities of the molluscs. The trends in the publications and patents were found to be gradually increasing in the recent times, which showed the greater interest of the researchers in this area ([@b0010], [@b0130]; [@b0170], [@b0355], [@b1485]). Molluscs of marine and estuarine origin were considered as the vital part of the traditional medicine, which were used as prospective sources of medicinally important products for many cultures around the world ([@b1205]) (Description S2; Table S1). The biological activities and secondary metabolites described from the molluscan extracts also found to be increased ([@b0610]). Molluscs were accounted for substantial emphasis in the exploration for biologically active metabolites, with more than 1,145 compoundsin the past few decades (Benkendorff, 2015). Around 52 % of the natural compounds identified from molluscan origin were not analyzed for any kind of biological activities, whereas lesser than 1 % of identified molluscan species were studied for the presence of bioactive secondary metabolites ([@b0010]). More recently, the molluscan natural products, and their synthetically formulated structural analogs were recognized in the clinical trials of various diseases ([@b1875]). For instance, the molluscan derived natural product, ziconotide have completed the clinical trials and sanctioned by the Food and Drugs Administration (FDA) for medication of severe pain ([@b1420]). Therefore, the rich diversity of molluscan species belonging to the marine and estuarine origin represents an unexploited resource of bioactive compounds to formulate high value compounds and therapeutic leads ([@b1430]). Recently, there is a substantial exploitation of molluscan derived compounds as pharmaceuticals and functional food supplements ([@b1430]).

The present review article extensively comprehended the health benefits, commercial significance, nutritive values, pharmacological potentials, secondary metabolites, biochemical classification of secondary metabolites, nutraceuticals, pharmaceutically prospective lead drugs supported by the list of publications and patents. This extensive review on the molluscan phylum would help in the future research activities, particularly in the development of functional foods, nutraceuticals, and therapeutic leads with multi-targeted bioactivities.

2. Materials and methods {#s0010}
========================

The review was carried out through extensive literature search, using electronic databases, and online search tools, such as Scifinder, Science Direct, PubMed, Google Scholar and MarinLit database. We have reviewed a total of about 479 articles to collect all the information with regard to molluscs, including the annual review papers titled as marine natural product reports between the periods 1984 to 2019 ([@b0770], [@b0775], [@b0780], [@b0785], [@b0790], [@b0795], [@b0800], [@b0805], [@b0810], [@b0815], [@b0820], [@b0825], [@b0830], [@b0215], [@b0220], [@b0225], [@b0230]; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2015; 2016; 2017; 2018; [@b0355]). The keywords "molluscs or molluscan" in MarinLit were used to summarize the published literatures on natural products reported from the molluscs. In Sci-Finder, the separate keywords, such as "bivalves", "cephalopods", and "gastropods" retrieved the detailed information about the molluscs. Keywords like "ω-conotoxin MVIIA", SNX-111", "ziconotide", "prialt" "elisidepsin", "kahalalides", "zalypsis", "jorumycin", "dolastatins", "dolastatin 10", "dolastatin 15", "LU-103793", "cematodin, ILX651", "synthadotin", "kulokekahilide-2", aurilide", "spisulosine ES-285", "keenamide A" were used in the PubMed search to obtain the details on the bioactive compounds and their applications. The search was carried out using the terms "antioxidant", "anti-inflammatory", "antihypertensive", "antidiabetic", "antimicrobial", "antiviral", "anticancer", "nutraceuticals", "functional foods", "fatty acids", "macrolides", "peptides", "polypropionates", "alkaloids", "sterols", and "terpenes" in combination with "bivalves", "cephalopods", and "gastropods" in Google search, Scifinder, and Science Direct, to obtain the reports of literature on the pharmacological activities and bioactive compounds of molluscs. Some selected species namely, "*Haliotis diversicolor*", "*Haliotis discus*", "*Babylonia spirata*", "*Babylonia zeylanica*", "*Bursa spinosa*", "*Chicoreus ramosus*", "*Paphia malabarica*", "*Villorita cyprinoides*", "*Meretrix meretrix*", "*Perna viridis*", "*Perna canaliculus*", "*Crassostrea madrasensis*", "*Uroteuthis* (*Photololigo*) *duvaucelii*", "*Cistopus indicus*", "*Sepia pharaonis*", "*Sepiella inermis*", "*Amphioctopus marginatus*" were reviewed in Google search. The searches of granted patents on molluscs were retrieved from Google patents. Unpublished papers and papers in non-English languages were considered as exclusion criteria. The latest date of literature searches was on 23^rd^ October, 2019. After reviewing the full paper, about 479 articles were regarded as potentially suitable publications for inclusion.

3. Commercial significance of molluscs of marine and estuarine origin {#s0015}
=====================================================================

The shares of the 104 aquaculture molluscan species (16.1 million metric tons) were estimated at US\$ 19 billion ([@b0860]). In 2014, the production of aquatic animals were recorded to 73.8 million tons, with assessed first-sale cost of US\$ 160.2 billion, in which the second largest class was found to be the molluscs with 16.1 million tons with an estimated value of US\$ 19 billion ([@b0860]). However, the global marine and estuarine molluscan production in 2016 was increased to 17.1 million tons with estimated first-sale cost of USD 29.2 billion ([@b0870]). According to FAO, 2020, the global production of molluscs, in particular, bivalves were found to be 17.7 million tonnes. The cephalopod species plays an important role in the exploited fisheries sectors all over the world, and began to receive more interest due to the cumulative export demands ([@b1570]). This might be due to the enhanced alertness about their dietary potentials ([@b1570]). Deteriorating catches of ground fishes have tempted to practice the potential non-traditional cephalopod species. During the last forty years, cephalopod stockings were increased from 1 million metric tons (1970) to 4 million metric tons (2010), whereas the share of squids, cuttlefishes and octopuses in world's fish market increased to 4 % (2010) with greater market price. Molluscan fishery in the Asian continent was largely comprised of squids (*Loligo duvauceli*, *Doryteuthis sibogae*), scallop (*Pecten yessoensis*) and cuttlefish (*Sepia aculeata*, *Sepia pharaonis*, *Sepia elliptica*, *Sepia officinalis*) ([@b0860]). Among the gastropods, abalone aquacultures were mainly found in China, and it was increased to five times in the recent years ([@b1940]). Notably, the molluscan aquaculture, particularly with reference to *Ruditapes philippinarum* (clam), *Patinopecten yessoensis* (scallop), *Mytilus edulis* (mussel), *Perna viridis* (Asian green mussel), *Perna canaliculus* (New Zealand green-lipped mussel) and *Anadara granosa* (clam) ([@b1235]), were gained momentum during the recent years. The availability of seafood in 2014 was amounted to 167.2 million metric tons (MMT), out of which the cephalopods alone were accounted for 4.3 MMT ([@b0860]). Among various cephalopods, *Illex argentines* and *Dosidicus gigas* were accounted for most marketed squids, whereas cuttlefish (300,000 tons) and octopus (350,000 tons) were found to be steady since 2008 ([@b0860]). After continuous growth, which started during the year of 2008, the cephalopod catches were found to be stable through 2015, but thereafter, exhibited a decreasing trend ([@b1205]). China, Peru and India were the major exporters of cuttlefish and squid, whilst China and Morocco were for octopus. The United States, Spain, Japan, Korea, Italy and Hawaii were the major consumers of cephalopods, whereas China and Thailand were the largest importers ([@b1205]). The production of squid was found to be higher than 77 %, followed by octopus (11 %) and cuttlefish (11 %) in 2016 ([@b0870]). Among bivalve molluscs, mussels, clams, scallops and oysters dominated as highly traded markets and farmed species. China was found to export bivalves three times as much as Chile, in 2016 ([@b2180]), whereas the former has significant domestic consumption, and produces more than 85 % of the world and European Union having the largest market for bivalves ([@b2180]). Globally, the bivalve production for human consumption was greater than 15 million tons per year (2010-2015), which was found to be 14 % of the total marine production in world. More than 85 % of bivalve production was reported from the aquaculture, and only 11 % was acquired from the wild conditions ([@b2180]). Production of oyster was found to be higher of about 54 %, followed by scallops (11 %), mussels (18 %) and clams (4 %) in 2016 ([@b0870]). The cupped oysters*, Crassostrea spp.* were found to be the major molluscan species (total of 28 %), followed by clam, *R. philippinarum* (total of 25 %), scallops, Pectinidae (total of 11 %) and other molluscs (total of 11 %), according to the world's aquaculture report ([Fig. 3](#f0015){ref-type="fig"} ) ([@b0870]). Ten major cultured molluscs were compared in [Table 1](#t0005){ref-type="table"} , according to their value and production in 2015, in which, *C. gigas* recorded a higher value of 3880.89 million USD and 5178707 tons production ([@b0865]). The inland aquaculture production of molluscs was higher for Asia, which was found to be 286 thousand tons of live weight, whereas there was no record of Inland molluscan aquaculture in the countries like Africa, America, Europe, and Oceania ([@b0870]). Marine and coastal aquaculture of molluscs were also higher for Asia of about 15,550 thousand tons of live weight, followed by those in Africa (6 thousand tons), America (574 thousand tons), Europe (613 thousand tons) and Oceania (112 thousand tons), in descending order ([@b0870]). According to [@b0860], the highest producer of molluscs was China with a production of 13418.7 thousand tons followed by Japan (376.8 thousand tons) and Korea (359.3 thousand tons). Bivalves were promoted as sustainable food items, and therefore, the demand has been increased during the recent years ([@b0870]). Estimated annual landings of mussels, oysters and clams in India during 2015 were 92,513 tons (CMFRI, 2015-2016), and therefore, were found as valuable fishery resources in various parts of the coastal regions of the penninsular India. The distribution and availability of major molluscan species, such as *P. viridis*, *P. canaliculus*, *P. malabarica*, *H. discus*, *M. edulis*, *S. pharaonis*, and *A. marginatus* around the world were depicted in Fig. S3 (retrieved from www.discoverlife.org, accessed on 12/10/2019).Fig. 3Percentage share of the major molluscan species produced in world aquaculture ([@b0870]).Table 1Comparison of ten major cultured molluscan species by their value and production in 2015 according to [@b0865]**SpeciesProduction (tons)Value (million USD)***Crassostrea gigas*51787073880.89*Ruditapes philippinarum*40495403708.93*Sinonovacula constricta*793708714.34*Anadara granosa*441303576.82*Patinopecten yessoensis*251907475.15*Mytilus chilensis*2087071711.4*Mytilus edulis*192271325.05*Perna canaliculus*76811494.86*Meretrix lusoria*64060141.03*Argopecten purpuratus*25988217.97

4. Health benefits and nutritive values of molluscs of estuarine and marine origin {#s0020}
==================================================================================

Studies on the health benefits and nutritive values of estuarine and marine molluscs as food and food supplements were interestingly increased in last years. Molluscs were found to play a significant role in water filtration, recycling of nutrients, soil-generation, and as bio-indicators of the environmental quality in all the aquatic habitats ([@b0100]). Rich and significant nutrient contents in the molluscs were reported to play prominent roles in the enhancement of immune systems in our body ([@b1205]). The dietetic composition of major molluscs, such as abalone, snail, mussel, oyster, scallop, clam, octopus, squid and cuttlefish were tabulated in [Table 2](#t0010){ref-type="table"} (accessed on 10/10/2019) (USDA, 2019a-2019i). Also, the saturated (SFA), mono-unsaturated (MUFA), and polyunsaturated (PUFA) fatty acids, along with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) contents of the above mentioned molluscs were compared ([Fig. 4](#f0020){ref-type="fig"} ) (USDA, 2019a-2019j). These data suggested that the PUFA and EPA contents were higher in oysters, followed by those in mussels and squid. PUFAs were found to be the key biochemical markers of cephalopods, whereas DHA and EPA were found to be vital for various human metabolic and physiological functions ([@b1880]). Long chain *n*-3 PUFAs were found to be essential to reduce the risk of numerous health problems, such as cardiovascular illnesses, type-2 diabetes, hypertension, inflammation, asthma and cancer ([@b1880]). The Asian communities consume molluscan species of marine and estuarine origin due to their health-promoting pluralities ([@b1230]). It was reported that some of the molluscan bioactivities and nutritive factors were retained even after the pre-treatments and cooking ([@b1920]).Table 2Dietetic composition of major molluscs based on United States department of agriculture (USDA), 2019**MolluscAbalone**[a](#tblfn1){ref-type="table-fn"}**Snail^b^Mussel^c^Oyster^d^Scallop^e^Clam^f^Octopus^g^Squid^h^Cuttlefish^i^**Protein (g)17.116.111.99.512.114.714.915.616.2Lipid (g)0.81.42.22.30.51.01.01.40.7Calcium (mg)31.010.026.08.06.039.053.032.090.0Iron (mg)3.193.53.95.10.41.65.30.76.0Magnesium (mg)48.0250.034.022.022.019.030.033.030.0Phosphorus (mg)190.0272.0197.0162.0334.0198.0186.0221.0387.0Potassium (mg)250.0382.0320.0168.0205.046.0350.0246.0354.0Sodium (mg)301.070.0286.0106.0392.0601.0230.044.0372.0Zinc (mg)0.821.01.616.60.90.51.71.51.7Copper (mg)0.20.40.091.60.020.10.41.90.6Manganese (mg)0.0403.40.60.020.10.030.030.1Selenium (µg)44.827.444.877.012.830.644.844.844.8Vitamin C (mg)2.008.08.00.005.04.75.3Vitamin A (µg)2.030.048.081.01.090.045.010.0113.0Vitamin E (mg)4.050.55000.71.21.20Vitamin D (IU)0.000.01.01.01.0000Vitamin K (µg)23.00.10.1000.20.100Cholesterol (mg)85.050.028.050.024.030.048.0233.0112.0[^2]Fig. 4Saturated (SFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids along with docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) contents of major molluscs, such as abalone, snail, mussel, oyster, scallop, clam, octopus, squid and cuttle fish based on the statistics of the United States Department of Agriculture (USDA), 2019 (accessed on 10/10/2019) (USDA 2019a; 2019b; 2019c; 2019d; 2019e; 2019f; 2019g; 2019h; 2019i.

Cephalopods were found to be rich in protein, and 80 % of their total fleshy material was considered to be the edible for human consumption ([@b0455]). The edible portions of these species were accounted for *n*-3 polyunsaturated fatty acids, minerals, vitamins along with essential amino acids including antioxidative selenium ([@b2280]). Several reports were available on the biological description, occurrence, proximate composition, and nutritional qualities of the cephalopod species ([@b1570], [@b1655]). Compositions of fatty acid profiles and its relation to seasonal or annual variations of cephalopods were previously studied ([@b1595]). Previous studies of *S. pharaonis*, *A. neglectus* and other species of cuttlefishes, octopuses and squids were reported to exhibit prominent lipid contents (\> 2 mg/100 g), which were found to be lesser than marine fishes ([@b0455], [@b2280]). Edible portions of cephalopod species, *U. duvauceli*, *S. inermis*, *S. pharaonis*, *C. indicus*, and *A. neglectus* were reported for greater contents of PUFAs ([Table 3](#t0015){ref-type="table"} ) ([@b0455], [@b1595]). The previous studies described that the cephalopods were found to be rich in protein, EPA, DHA, micro/macro minerals, vitamins, amino acids, and therefore, these species could be regarded as an effective health food for human consumption ([@b0455]). Previous studies of edible molluscs, such as Indian squid *U.* (*Photololigo*) *duvaucelii*, the veined octopus *A. marginatus*, the spineless cuttlefish *S. inermis*, and the oyster *Crassostrea bilineata* were reported for their greater contents of protein with prominent essential to non-essential amino acid ratios ([@b1265]). These were also reported for their prominent levels of *n*-3/*n*-6, EPA and DHA fatty acid ratio, which suggested their utilisation as balanced diet ([@b1265]).Table 3Nutritional profiling of major species of molluscs**Nutritional parametersBivalvesCephalopodsGastropods**[a](#tblfn2){ref-type="table-fn"}***Paphia malabarica***[a](#tblfn2){ref-type="table-fn"}***Villorita cyprinoides***[b](#tblfn3){ref-type="table-fn"}***Crassostrea bilineata***[c](#tblfn4){ref-type="table-fn"}***Perna viridis***[b](#tblfn3){ref-type="table-fn"}***Amphioctopus marginatus***[d](#tblfn5){ref-type="table-fn"}***Amphioctopus neglectus***[d](#tblfn5){ref-type="table-fn"}***Cistopus indicus***[d](#tblfn5){ref-type="table-fn"}***Uroteuthis duvauceli***[d](#tblfn5){ref-type="table-fn"}***Sepia pharaonis***[d](#tblfn5){ref-type="table-fn"}***Sepia inermis***[e](#tblfn6){ref-type="table-fn"}***Chicoreus ramosus***Lipid (%)1.772.271.191.471.582.501.751.752.561.300.39Cholesterol (mg/100g)59.0256.2734.7496.699.43103.65128.64191.65320.15307.5128.7True protein (mg/100 g)12.6411.1518.367.1413.541202.741850.211951.391449.031874.212.89**Macronutrients (mg/100g)**Na118.5092.0016.571967.257.65172.45170.14171.98170.18172.7795.00K94.2360.2148.251450.5020.05144.56184.83176.13201.2134.67149.6Ca34.2528.5217.9228713.3273.7254.0472.82108.4179.7338.10P583.62534.2392.71ND83.7286.0766.3385.6380.4072.3798.00Mg36.7525.8616.5464.3312.5592.83104.78127.36127.28134.6775.79**Micronutrients (mg/100g)**Mn2.031.751.38ND0.046.396.516.576.926.430.11Cu0.460.300.860.050.263.557.541.335.575.330.16Zn3.013.264.991.551.0613.0814.177.2115.188.341.27Fe7.645.652.446.102.217.446.610.427.798.451.65Se (μg/100g)30.1527.270.020.040.069.319.459.548.959.3430.44**Vitamins**Retinol A (IU)39.4641.118.0911.8999.4215.358.3926.5121.654.8121.89Cholecalciferol D3 (IU)161.29183.28489.20410.0093.684.393.301.613.511.521.21*α*-tocopherol E (IU)0.390.320.210.1516.6111.433.541.455.2911.2655.82Phylloquinone K1 (μg/100g)0.750.651.842.721.480.011.580.010.26NDNDAscorbic acid C (IU)10.211.3648.3612.1442.622.201.802.900.702.8045.45**Fatty acid (% total fatty acids)**Total SFA33.8447.7743.0139.5635.85879.25461.62591.00720.19398.2629.14Total MUFA23.1525.5726.7921.6329.18477.06485.54180.95515.28166.2920.94EPA7.683.577.577.958.29238.84135.57213.54360.96119.2515.83DHA14.353.228.689.6014.70645.05374.68534.89599.90267.6317.17Total PUFA34.3318.4626.3525.3831.441076.25660.86845.781211.27594.949.77**Amino acids (mg/100g)**Histidine14.6413.54ND38.110.0012.3016.016.574.313.1969.30Methionine16.6718.3290.0025.8150.0022.107.354.412.151.32106.20Valine29.4730.57150.0059.9510.0028.3712.096.183.432.62112.90Threonine27.2329.95120.0061.4070.0030.1512.186.484.272.11186.30Isoleucine29.6231.12140.0052.2160.0033.1213.057.213.472.44130.00Leucine42.9548.35220.00116.3090.0046.5719.2811.395.073.11321.60Lysine43.5741.67160.0091.30140.0036.2619.1112.514.073.37263.00Phenylalanine28.2033.11110.0063.6390.0034.199.145.253.102.25117.30Total AA551.78566.122620.001596.771530.00561.50270.03142.1874.6347.353836.50Total EAA285.29300.201340.00697.53870.00316.19141.4475.1139.2826.481857.90Total NEAA266.49265.921280.00899.24660.00245.31128.5967.0735.3520.871978.60[^3][^4][^5][^6][^7][^8]

During the recent years, the gastropods are gaining greater significance among molluscs due to their commercial potentials. Previous studies were reported with greater percentages of proteins in the predator gastropod whelks, when compared to the herbivore gastropods (Zarai et al., 2011). Predatory carnivore gastropods, such as *Chicoreus ramosus* ([@b1710]), *Hexaplex trunculus* (Zarai et al., 2011), *Thais haemastoma* ([@b0120]) and *Rapana venosa* ([@b0360]) were reported for their higher protein contents. Nutritional profiles of the gastropods were found to vary according to the type of organisms, body parts, seasonal changes, collection sites, spatial changes, temporal variations, and reproductive cycles ([@b1885]). The lipid content was found to be lesser in the predatory gastropods than those in the herbivorous gastropods ([@b1710], [@b0120]). The visceral lipid content was greater when compared to the foot tissues, and the visceral tissues were considered as the lipid storing part of the gastropods. Usually, visceral tissues in the larger gastropods were not recommended for consumption, and the foot tissues were typically consumed by the people ([@b1785]). Therefore, the previous studies concluded that the foot tissues were suitable for human diet, due to higher protein and lesser lipid contents ([@b1280]). The fatty acid composition, especially PUFA contents along with DHA and EPA were previously reported in the various gastropods, particularly in the snails ([@b0285], [@b1280]). Gastropods were found to possess various minerals, such as potassium, sodium, selenium, zinc, iron, and sulphur ([@b1280]). Also, the essential amino acid components were considerably higher in the gastropods, such as *Chicoreus virginineus*, *Phalium glaucum*, *Rapana rapiformis*, and *Tonna dolium* ([@b0105]). The branched murex, *C. ramosus* from Gulf of Mannar was studied for their nutritive values, and the studies suggested that these low-valued gastropod species could be considered as valuable depot of essential nutritional elements, functional foods, and as a health food for human consumption ([@b1815]). It exhibited lesser sodium/potassium ratio with greater contents of calcium, phosphorus, and antioxidative mineral, selenium. Therefore, *C. ramosus* could be utilized to reduce the risk of hypertension, and cardiovascular diseases along with higher bone mineralization ([@b1815]). These studies described the nutritional qualities of gastropods, and suggested that these could contribute towards the people's diets, as nutritional health food, particularly in the developing countries.

Bivalve molluscs are prominent seafoods at the coastline regions, and were found to constitute a dominant share in the global trade markets (Chakraborty, Chakkalakal, & Joseph, 2014a; [@b2210]). However, these were not comprehensively investigated for their dietary and nutritional potentials. Bivalves were found to be the potential resources of *n*-3 polyunsaturated fatty acids, comprising of EPA/DHA (Chakraborty, Joseph, & Chakkalakal, 2014a). Bivalve molluscs were potential sources of anti-inflammatory agents (E and D resolvins), which were found to play prominent roles to combat the biosynthesis of inflammatory prostanoids (Chakraborty, Joseph, & Chakkalakal, 2014b). In general, these species were reported to provide an inexpensive source of proteins, minerals, amino acids, and vitamins ([@b0090]). The bivalves, *Ruditapes decussatus* and *Mytilus galloprovincialis* collected from the Mediterranean Sea were reported to exhibit greater contents of lipid and protein ([@b1775]). The Asian hard clam, *Meretrix lusoria* and *M. meretrix* displayed prominent nutritional qualities ([@b1965], [@b2210]), and were considered as low-valued health food items. In the view of nutritional qualities, bivalves were positioned next to the finfish and prawns. Nutritional qualities of green mussels (*P. viridis*) and edible oysters (*C. madrasensis*) were reported previously, and were suggested as the substitutes to equilibrate the greater consumption of inflammatory *n*-6 fatty acids ([Table 3](#t0015){ref-type="table"}) ([@b0420], [@b0415]). The nutritional quality parameters, such as mineral composition, fatty acids, glycogen, cholesterol, vitamins, carotenes, and the commercial quality indicators of *Chamelea gallina* were studied previously ([@b1580]). Proteins, minerals, lipids, glycogen, along with minor components of lipophilic and hydrophilic nature were found to contribute towards the nutritive importance and organoleptic features of clams ([@b1580]). The historical seafood, *M. meretrix* was considered as the valued resources of ancient Chinese therapeutics ([@b2210]). Nutritive values of *P. malabarica and V. cyprinoides* were described by their greater contents of *n*-3 PUFAs (\> 15 % total fatty acids, TFA), EPA (\> 3 % TFA), and DHA (\> 3 % TFA) ([@b1125]). Greater calcium and phosphorus contents (\> 550 mg/100 g wet tissue), higher vitamin A (\> 35 IU) and D~3~ (\>160 IU), along with higher levels of selenium Se (\> 25 μg/100 g wet tissue) ([@b1125]), were also reported in these bivalve clams ([Table 3](#t0015){ref-type="table"}). These previous studies established the nutritional importance of marine and estuarine molluscs for use as nutritional health foods, particularly in coastal regions of the world.

5. Nutraceuticals, functional foods and high value compounds from the marine and estuarine molluscs {#s0025}
===================================================================================================

In the recent days, the concept of nutraceuticals and functional foods were interestingly increased. Nutraceuticals and functional foods became a part of consumer's daily diets, as a preventive healthcare measure against increased life-style diseases (Mordor Intelligence, 2015-2019). The nutraceuticals signified the functionalities of pharmaceuticals in the food itself. Therefore, the food supplements as daily diets could prevent the diseases, and these could lead to the reduced usage of synthetic drugs with severe side effects. The global market of nutraceuticals were valued at around USD 250 billion in 2014, and believed to reach approximately USD 385 billion by 2020, at a CAGR (compound annual growth rate) of 7.5 % from 2016 to 2021 (Mordor Intelligence, 2015-2019). Among various marine organisms, molluscs occupied an integral part in the formulation of several nutraceuticals and could be used as functional foods to improve the health benefits ([Table 4](#t0020){ref-type="table"} ; [Fig. 5](#f0025){ref-type="fig"} ). For example, the dried abalone powder was commercialized as a nutraceutical product in New Zealand ([@b1285]). The nutraceutical product, ABA-Active, an abalone powder from *Haliotis iris* was reported to strengthen the body, enhance the liver function, beneficial to the heart, promotes sexual function, and helps to prevent anemia (Aroma New Zealand Ltd., 2019). A nutraceutical supplement was marketed from *P. viridis* (Cadalmin^TM^ Green Mussel extract), which exhibited potent *in vivo* and *in vitro* anti-inflammatory effects against pro-inflammatory prostanoids, was found to be effective against arthritis ([@b0405]; Chakraborty et al., 2012).Table 4Commercialized nutraceutical products reported from different molluscan species**Commercial nutraceutical productsSpeciesTherapeutic propertiesReferences**Oyster Plus*Crassostrea sp.* (Oyster)Improves men's reproductive health, supports immunity, health and vitality[@b0975]Cadalmin^TM^ Green Mussel extract (GMe)*Perna viridis* (Green mussel)Effective in chronic joint pain and arthritis and improves cardiovascular function and inflammatory disordersChakraborty et al., 2012Abalone*Haliotis sp.* (Snail)Improves eye health, general health and vitality[@b0980]ABA-Active, an abalone powder*Haliotis iris* (Snail)Strengthens the body, enhance the liver function, beneficial to the heart, promotes sexual function and helps to prevent anemiaAroma New Zealand Ltd, 2019Lyprinol®*Perna canaliculus* (Green-lipped mussel)Antiinflammatory activity against cyclooxygenase-2 and 5-lipoxygenase inflammatory enzymes, activities against arthritis and asthma[@b2165]Mussel 6000*Perna canaliculus* (Green-lipped mussel)Nutritional support for joint stiffness, comfort, lubrication and mobility and overall joint repair[@b0985]Aquatone*Perna canaliculus* (Green-lipped mussel)Effective in retaining healthy joints[@b1525]GlycOmega-PLUS™^91^Green-shell mussel powderReduce joint pain and to enhance joint mobilityAroma New Zealand Ltd, 2019Seatone®*Perna canaliculus* (Green-lipped mussel)Antiinflammatory supplement[@b0630]Bioskincare™*Helix aspersa*Cosmeceutical, to repair scars, prevent and remove stretch marks and to firm breasts[@b0165]BioLex*Perna canaliculus* (Green-lipped mussel)Osteoarthritis[@b1915]Biolane™*Perna canaliculus* (Green-lipped mussel)Arthritis[@b0510]Fig. 5Numbers of taxa in different classes of molluscs (particularly, gastropods, cephalopods and bivalves) that were reported for their uses in medicinal applications (traditional Chinese medicins, traditional Indian medicine, nutraceuticals and pharmaceuticals) ([@b0125]). No record of medicinal applications with regard to the molluscan classes, such as Monoplacophora, Scaphopoda, Solenogastres, Caudofoveata and Polyplacophora was available.

Anti-inflammatory composition of Cadalmin^TM^ Green Mussel extract from *P. viridis* was marketed as Musseltone®, which demonstrated the potential activities against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes (Chakraborty, Joseph, & Chakkalakal, 2014a). Natural remedies of New Zealand green-lipped mussel, *P. canaliculus* were promoted as anti-inflammatory agents to treat the progression of the ailments of joint and connective tissues, as well as the symptoms of arthritis ([@b2010]). Also, several novel anti-inflammatory omega-3 PUFAs were identified from the extracts of *P. canaliculus* ([@b2010]). Commercial freeze-dried extract of *P. canaliculus* was found to down-regulate the inflammatory responses ([@b0155]), whereas its lipid fraction was marketed as Lyprinol®, which demonstrated the potential activities against arthritis ([@b2165]) and asthma ([@b0960], [@b1015]). An anti-arthritic nutraceutical from *P. canaliculus* was marketed as Biolane™, and its activities were compared with the standard anti-arthritic agents like chondroitin sulfate, lyprinol, and glucosamine sulfate ([@b0510]). Biolane™ was reported to exhibit broad-spectrum of activities including inhibition of pro-inflammatory PGE, COX-2, along with anti-platelet aggregation, and fibrinolytic potencies compared to other agents ([@b0510]). All these studies supported the oral administration of the green lipped mussel extract to control the inflammatory conditions ([@b0510]). A wide range of nutraceuticals and functional foods have been developed from this species, including mussel extract, that claimed to have five times greater anti-inflammatory properties than the mussel powder (Aroma New Zealand Ltd, 2019). Another product, GlycOmega-PLUS™ (Greenshell™ mussel powder) was produced from the cold extracted green lipped mussel, which was clinically proved to reduce joint pain, and enhance joint mobility (Aroma New Zealand Ltd., 2019). It was proved as rich sources of glycosaminoglycans, the significant components of cartilage, and synovial fluids in joints (Aroma New Zealand Ltd, 2019). GlycOmega-Oil™, a greenshell™ mussel oil was a rich source of DHA and EPA omega-3 fatty acids, along with 30 other essential fatty acids. This product used for treating the joint, respiratory, and cardiovascular diseases, along with maintaining balanced HDL (high-density lipoprotein) and triglyceride levels (Aroma New Zealand Ltd, 2019). The cost of the mussel powder was \$AUD 150/kg, \$ 1600/kg for the extract and ∼\$ 16,000/kg for the Lyprinol® ([@b0125]). The oyster powder developed from the Pacific oyster, *C. gigas* was promoted as a dietary supplement, which was found to be beneficial for maintaining the blood pressure, cardiovascular health, arthritis, skincare, rheumatism, and liver problems (Aroma New Zealand Ltd, 2019). A nutritional supplement, Seatone® developed from *P. canaliculus* was used as an anti-inflammatory functional food product ([@b0630]). The cowrie shells (Cypraeidae) were incorporated in Chinese traditional medicines ([@b1055]), and was patented for use in the dental fillings ([@b2145]). Mucus of *C. aspersa* was incorporated in the commercially available cosmeceutical, branded under Bioskincare™, which was claimed for its effects on repairing scars, prevent and remove stretch marks, and to firm the breasts ([@b0165]).

6. Bioactive secondary metabolites from marine and estuarine molluscs {#s0030}
=====================================================================

The reports of marine natural products series described more than 1334 secondary metabolites between the periods 1984 to 2017 from molluscs ([@b0770], [@b0775], [@b0780], [@b0785], [@b0790], [@b0795], [@b0800], [@b0805], [@b0810], [@b0815], [@b0820], [@b0825], [@b0830], [@b0215], [@b0220], [@b0225], [@b0230]; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2015; 2016; 2017; 2018; [@b0355]). A year-wise comparison of numbers of secondary metabolites isolated from the molluscs was depicted in [Fig. 6](#f0030){ref-type="fig"} . Previous reports of literature described a total number of 948 compounds from the gastropods, 190 from the bivalves, and 24 secondary metabolites from the cephalopods ([@b0095], [@b0125]). These reports suggested that most of the chemical studies andthe isolation of bioactive secondary metabolites were more focused on gastropods, followed by bivalves, and cephalopods. Therefore, we have focused to review the bioactive secondary metabolites, particularly from these three prominent classes of molluscs.Fig. 6Aggregate numbers of reported secondary metabolites and papers published (after [@b0770] to 2002, [@b0215] to 2018, Carrol et al., 2019).

6.1. Cephalopod molluscs {#s0035}
------------------------

Cephalopods were considered as significant resources of bioactive metabolites with prominent bioactive potentials ([@b0365], [@b0460]). Knowledge of bioactive compounds from these organisms would help to develop newer pharmacological agents ([@b0365]). Even though, limited research works and fewer publications were available on the biologically active molecules from these species, the important cephalopod metabolites were illustrated ([Fig. 7](#f0035){ref-type="fig"} , Fig. S4). The pigments, adenochromines **1**-**3** were reported from *Octopus vulgaris* ([@b1685]). Arsenolipids **4**-**5** were reported from a squid, *Todarodes pacificus* ([@b1540]). Cyclophosphamine extracted from squid ink was a well-known chemotherapeutic drug ([@b2270]). Cytotoxic tyrosinase was isolated from *S. officinalis* ([@b1765]). Novel cardioactive peptides were purified from the Japanese octopus, *Octopus minor* ([@b1100]). Astaxanthin and its ester derivatives were found to be the major carotenoids in octopus and cuttlefish species ([@b1410]). The Octopodidae cephalopod, *A. neglectus* was reported to contain four macrocyclic lactones **6**-**9** with antihypertensive potencies, among which macrocyclic lactones with furo\[1,4,8\]trioxacyclohexadecine-12, 19-dione functionality, **7** exhibiting potent protective properties against angiotensin-II induced cardiac hypertrophy at 25 μg/mL on the H9C2 cell lines in the *ex-vivo* analyses ([@b0465]). Spineless cuttlefish, *S. inermis* was found to possess four chromenyl derivatives, named as methyl 7-ethyl-hexahydro-8a-methyl-2*H*-chromene-4-carboxylate **10** and methyl 1-acetoxy-hexahydro-3-methyl-3-propyl-1*H*-isochromene-4-carboxylate **11** with selective *in vitro* antioxidative/anti-inflammatory potentials ([@b1255]). The same species was reported for 11-(hexahydro-8-methoxy-4-methyl-1*H*-isochromen-4-yloxy)-11-hydroxyethyl pentanoate **12** and methyl 9-(tetrahydro-3-oxo-3*H*-isochromen-5-yl)hexanoate **13** with antioxidative and anti-hyperglycemic potentials ([@b1260]). A cephalopod mollusc, *A. marginatus* was reported antioxidant and anti-inflammatory compounds, such as sterol derivative **14** and octahydroazulenopyrandione **15** ([@b0370]). Three antioxidative oxygenated terpenoids were reported from *U. duvaucelii* with anti-inflammatory activities, and their structural attributions elucidated as C19 furano-norditerpenoid **16**, irregular C15 sesquiterpenoid **17** and C20 diterpenoid **18** ([@b0470]).Fig. 7Structures of compounds isolated from cephalopod molluscs. **1**-**3** Adenochromines, **4**-**5** Arsenolipids, **6**-**9** Macrocyclic lactones, **10**-**13** Chromenyl derivatives, **14** Sterol derivative, **15** Octahydroazulenopyrandione, **16**-**18** Oxygenated terpenoids.

6.2. Gastropod molluscs {#s0040}
-----------------------

Numerous bio-potent secondary metabolites were identified and characterized from the gastropod molluscs, and some of the important gastropod metabolites were illustrated ([Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"} ). A linear homosesterterpene, granuloside **19** was isolated from gastropod, *Charcotia granulosa* ([@b0675]), and diterpene metabolites thuridillins **20**-**21** were isolated from *Thuridilla splendens* ([@b1895]). The Δ^8^ unsaturated 4,4-dimethyl and 4-methyl sterols were isolated from *Cellana grata* and *C. toreuma* ([@b1200]), and pyranone ester derivatives or analogs **22**-**25** were characterized from *Onchidium sp.* ([@b0330]). An anti-leishmaniasis compound, 5*α*, 8*α*-epidioxycholest-6-en-3*β*-ol was characterized from *Dolabrifera dolabrifera* ([@b0620]). Mycosporine-type of amino acids **26**-**28** were isolated from the protective ink of *Aplysia californica* (Sea hare) ([@b1185]). The polypropionate derivatives, niuhinone A-C **29**-**31** were identified from the carnivorous mollusc, *Philinopsis speciosa*, and an herbivore mollusc, *Bulla occidentalis*. These suggested that the origin of these metabolites in *P. speciosa* could be due to the consumption of *Bulla sp.* ([@b0640], [@b0665])*.* A guanidine-bound terpene derivative **32** was identified from *Doto pinnatida* ([@b1690]), whereas an asteriscane sesquiterpenoid **33** was afforded from *Phyllodesmium magnum* ([@b1365]). Rare pyran-enclosed cladiellane diterpene derivatives, tritoniopsin A-D **34**-**37** were isolated from *Tritoniopsis elegans* and its feed *Cladiella krempfi* (coral) ([@b0560]). Novel diterpenoids **38**-**39** and chromoculatimine A-B **40**-**41** were identified, and the tissue localization studies revealed that these diterpenes were obtained from their mantle and internal organs (Suciati, Lambert, & Garson, 2011). An isopentyl-containing alkaloid, tambjamine K **42** was identified from *Tambja ceutae* ([@b0335]). The clerodane diterpenes palmadorin A-C **43**-**45** were isolated from a nudibranch, *Austrodoris kerguelenensis* ([@b0725]) and sesterterpenoid, ansellone A **46** was isolated from *Cadlinalutero marginata* ([@b0685]). Extraction of digestive and hermaphroditic glands of *Aplysia fasciata* (sea hare) yielded sesquiterpenoids **47**-**49**, acetogenin **50**, and diterpenoid **51** ([@b1090]).Fig. 8Structures of compounds isolated from gastropod molluscs. **19** Homosesterterpene, granuloside, **20**-**21** Thuridillins, **22**-**25** Pyranone ester derivatives, **26**-**28** Mycosporine-type amino acids, **29**-**31** Polypropionate derivatives, niuhinone A-C, **32** Guanidine-bound terpene derivative, **34**-**37** Tritoniopsin A-D, **38**-**39** Diterpenoids, **40**-**41** Chromoculatimine A-B, **42** Tambjamine K, **43**-**45** palmadorin A-C, **46** Ansellone A, **47**-**49** Sesquiterpenoids, **50** Acetogenin, **51** Diterpenoid, **52**-**55** Aplysiopsene A-D, **56** Manoalide, **57** Secomanoalide, **58** Ketosteroid derivatives, **59**-**60** Cyclic depsipeptides, **61** Crispatenine, **62** Pyrone compound, **63**-**67** Lignarenones, **68**-**69** Fusaripyrones, **70**-**71** Aplysiols, **72**-**75** Chamigrane sesquiterpenoids, **76** Malyngamide, **77** Sesquiterpenoid, **78** Diterpenoid, **79** Isocopalane diester, **80** Scalarane, **81**-**82** Labdane, **83** Siphonarienolone, **84**-**85** Caulerpenyne metabolites, **86**-**87** Kahalalide R-S, **88**-**91** Bisabolene typed sesquiterpenes, **92**-**93** Miscellaneous, **94**-**95** Pyrone and its possible peroxyanalog, **96**-**97** Elysiapyrone metabolites A-B, **98** Tridachiahydropyrone, **99***Trans*-decalin, **100**-**102** Sesquiterpene derivatives, **103**-**104** C15-halogenated derivatives, **105** (3*Z*)-bromofucin, **106** Laurinterol, **107** Debromolaurinterol, **108**-**109** Degraded sterols.Fig. 9Structures of compounds isolated from gastropod molluscs. **110** (+)-Austrodoral, **111**-**112** Pelseneeriols, **113** Norrisolide, **114** Dorisenone C, **115**-**116** Haterumaimides, **117** 3*β*-Hydroxychlorolissoclimide, **118**-**119** Scalarane metabolites, **120**-**122** Sesquiterpenes, **123** (−)-Tochuinyl acetate, **124** (−)-Dihydrotochuinyl acetate, **125** Austrodoric acid, **126**-**129** Placidenes C-F, **130**-**132** Acylglycerols, **133**-**136** Labdane diterpenes, **137**-**138** Polyhydroxylated steroids, **139-140** Membrenones A-C, **142** Siphonarienolone, **143** Siphonarienedione, **144** Siphonarin B, **145** Malyngamide-S derivative, **146**-**149** Diterpene metabolites, **150**-**152** Sesquiterpenes, **153** Progesterone analog, **154** Johnstonol, **155** Pacifenediol, **156** Pacifidiene, **157**-**158** Tryptophan-based dipeptides, **159** Auriculol, **160** Non-halogenated sesquiterpene, **161** Puertitol-B acetate, **162** Caespitenone, **163** 8-Acetyl-caespitol, **164** Dactylopyranoid, **165** Isopinnatol B, **166**-**167** Ascobullins A-B, **168**-**170** Tridachiapyrones G-J, **171**-**172** Tridachiahydro pyrones B-C, **173** Scutinin A, **174**-**175** Scutinin B, **176**-**177** Tetrahydropyran monodontins A and B, **178** Bromo-chloro-diterpenoid dolabellol A, **179**-**181** Pustulosaisonitriles 1-3, **182** Spurillin A, **183** Farnesol derivative, **184** Diterpene spurillin B, **185** Methylsarcoateanalog, **186** 2R Secogorgosterol, **187** Bisepoxide, **188**-**189** Isobisglaucumlides B-C, **190** Isosarcophine, **191** Diacylguanidineactinofide, **192**-**194** Ulapualides C-E, **195**-**200** Spongian-16-one analogs, **201** Cembrane-type diterpenoid, **202** Sesquiterpenoid Ramosane, **203** Polyether macrocyclic lactone, **204** Lactonic steroid, **205**-**206** Unusual Δ^5^ sterols, **207** 15-Acetoxy-ent-pallescensin-A, **208** Dendocarbin-A, **209** Euryfuran, **210** Drimane ester.

The *α*-pyrone polyketides, aplysiopsene A-D **52**-**55** were isolated from herbivorous *Aplysiopsis formosa* (slug) ([@b0565]). Chemical investigation of *Chromodoris willani* reported for its deoxy analogs of manoalide **56** and secomanoalide **57** with anti-microbial activity ([@b2030]). An anti-fungal compound Kabiramide B was reported from the Pacific nudibranch *Hexabranchuss anguineus* ([@b1415]). The prosobranch mollusc, *Onchidiopsis variegate* was reported for ketosteroid derivative **58** ([@b1820]), and sacoglossan mollusc, *Elysia grandifolia* was reported to harbor two new members of cyclic depsipeptides **59**-**60** in the kahalalide family ([@b1995]). Absolute conformation of crispatenine (sesquiterpenoid), **61** formerly identified from *Tridachia crispata* ([@b0940]), was recognized by its enantioselective synthesis ([@b0275]). A new pyrone compound **62** was reported from *Placobranchus ocellatus* (Manzo et al., 2005a), and aromatic benzene-enclosed compounds, named as lignarenones, were reported from *Scaphander lignarius* **63**-**67** ([@b1795]). The polypropionate analogs, fusaripyrones A and B **68**-**69** were reported from Mediterranean *Haminoea fusari* ([@b0660]). Polyether triterpenes, named as aplysiols A and B **70**-**71** were identified from *Aplysia dactylomela* (sea hare) collected from the South China Sea (Manzo et al., 2007a), and the chemical investigation of this same species from Madagascar afforded halogenated chamigrane sesquiterpenoids **72**-**75** ([@b1865]). Another sea hare, *Bursatella leachii* was reported to produce 7*R*-configured malyngamide **76** ([@b1960]). A sesquiterpenoid **77** and a diterpenoid **78** were isolated from *H. sanguineus* (Spanish dancer mollusc) ([@b2250]). The isocopalane diester **79** was isolated from a previously unrevealed gastropod of Marion Island ([@b2100]). A 12-keto scalarane type of compound, **80** was reported from *Glossodoris averni* (Queensland, Australia), and *G. pallida* (Hainan, China) (Manzo et al., 2007b). The labdane class of diterpenoids **81**-**82** were reported from *Plevrobranchaea meckelii* ([@b0575]). The pulmonate, *Siphonaria lessoni* was the major source of a nor-homolog of well-known metabolite, siphonarienolone **83** ([@b1755]). A cytotoxic alkaloid lamellarin N was reported from *Lamellaria sp.*, and further structure-activity analyses on lamellarin D were carried out ([@b1660]). The sacoglossan mollusc, *Elysia cf. expansa* collected from Mandapam, India afforded two caulerpenyne-type metabolites, dihydrocaulerpenyne **84** and expansinol **85** ([@b0550]).

The cyclic depsipeptides, kahalalide R-S, **86**-**87** were reported from *E. grandifolia* ([@b0085]). Bisabolene-type sesquiterpenes **88**-**91** were identified from the crude extracts of *A. dactylomela* ([@b0295]). An antitumor compound, aplyronine A was isolated from *A. kurodai* (Yamada, Ojika, Ishigaki, & Yoshida, 1993). Chemical investigation of Australian mollusc, *Glossodoris atromarginata* was found to possess the compounds, **92** and **93**, for the first time (Andersen, Desjardine, & Woods, 2006). The pyrone **94** and its possible peroxy analog **95** from *Placobranchus ocellatus* were reported previously (Manzo et al., 2005a). [@b0650] reported the presence of elysiapyrone metabolites A-B **96**-**97** from *Elysia diomedea*. The tridachiahydropyrone metabolite, **98** was isolated from *T. crispata* and a *trans*-decalin compound, **99** was isolated from *T. reticulatus* ([@b0945], [@b1335]). Sesquiterpene derivatives **100**-**102** were isolated from *A. dactylomela* ([@b0710]) with *in vitro* anti-tumor activity. The C15-halogenated derivatives **103**-**104** were identified from *A. dactylomela* (Manzo et al., 2005b). The metabolite (3*Z*)-bromofucin **105** was isolated from *A. parvula* extracts ([@b1445]), whereas the bioactive laurinterol **106** and debromolaurinterol **107** were reported from *A. kurodai* ([@b2020]). *B. leachii* was the predominant source of cytotoxic metabolites, such as hectochlorin and deacetyl derivatives ([@b1955]). The degraded sterols, such as aplykurodinone 1-2 (**108** and **109**) were purified from the skin extract of mollusc, *Syphonota geographica* ([@b0925]). Derivatives of dolastatin 11 from *D. auricularia* ([@b1645]) and nor-sesquiterpenoid, (+)-austrodoral **110** from *A. kerguelenensis* (Antarctic mollusc) were previously reported ([@b0920]). Furanosesquiterpene alcohol derivatives, pelseneeriols-1 **111** and 2 **112** were reported from *Doriopsilla pelseneeri* ([@b0910]). Dodecadienonyl-benzoquinone and hydroquinone derivatives were purified from *Leminda millecra* (African gastropod) ([@b1450]). Norrisolide **113** was isolated from *Chromodoris norrisi* ([@b1040]) and dorisenone C **114** was identified from *C. obsolete* ([@b1470]). The cytotoxic components, haterumaimides L **115** and M **116** along with 3*β*-hydroxychlorolissoclimide **117** were obtained from *Pleurobranchus albiguttatus* and *P. forskalii* ([@b0895]).

Isolation of scalarane-framework metabolites **118** and **119** from *G. rufomarginata* was reported previously ([@b0950]). Sesquiterpenes **120**-**122** were fractionated from *Phyllidiella pustulosa* found at South China ([@b1340]). The sesquiterpenes (−)-tochuinyl acetate **123** and (−)-dihydrotochuinyl acetate **124** were identified from *Tochuina tetraquetra* ([@b2185]). Pyrone polypropionate, cyercene was reported by [@b2105] from the Mediterranean *Cyerce cristallina*. Austrodoric acid **125** from Antarctic *A. kerguelenensis* was previously reported by [@b0920]. Asymmetrical polypropionate derivatives named as placidenes C-F **126**-**129** were characterized by [@b0670] from *Placida dendritica*. Chemical investigation of diterpenoid acylglycerol fraction from the Antarctic gastropod, *A. kerguelenensis* yielded acylglycerols **130**-**132** ([@b0915]). Labdane diterpenes **133**-**136** were identified from *T. peruvianus* (pulmonate) along with cytotoxic polyhydroxylated steroids **137**-**138** ([@b0715], [@b0720]). Three polypropionate enclosed compounds, named as membrenones A-C **139**-**141** were extracted from *Pleurobranchus membranaceus* by [@b0570]. Chemical investigation of *Siphonaria grisea* reported the presence of polypropionates, which were named as siphonarienolone **142** and siphonarienedione **143** ([@b0310]), and their stereochemistries were also established ([@b1550]). Siphonarin B **144** was reported from *Siphonaria zelandica* and *S. atra* ([@b1035]). A novel malyngamide S derivative **145** was reported from the mollusc *B. leachii*, and the compound was found to exhibit potential anti-inflammatory activities ([@b0065]). Wide range of diterpene metabolites **146**-**149** and new sesquiterpenes **150**-**152** were reported by [@b0845] from the Sardinian Sea hare *Aplysia punctata*. The progesterone analog **153** was isolated by [@b0955], from the nudibranch *Aldisas maragdina* (Spain). Extensive NMR assignments of the *A. dactylomela* metabolites, such as johnstonol **154**, pacifenediol **155** and pacifidiene **156** ([@b1180]), along with tryptophan-based dipeptides **157** and **158** ([@b0060]), were previously reported. Another sea hare, *Dolabella auricularia* was found to contain a novel cytotoxic squalene metabolite, named as auriculol **159** (Kigoshi, Hayashi, & Uemura, D 2001). A non-halogenated sesquiterpene **160** was found from *Aplysia sp.*, which was possibly a rearranged product of a known chamigrane ([@b0840]). New sesquiterpenes, puertitol-B acetate **161**, caespitenone **162** and 8-acetyl-caespitol **163**, along with diterpenoids, such as dactylopyranoid **164** and isopinnatol B **165** with prospective bioactivity profiles were characterized from *A. dactylomela* ([@b2150]). The sesquiterpene metabolites, ascobullins A **166** and B **167** were reported from *Asco bullaulla* ([@b0930]). Polypropionate pyrones, such as tridachiapyrones G-J **168**-**170** and tridachiahydropyrones B-C **171**-**172** were reported from the mollusc, *P. ocellatus* ([@b0890]).

The unreported odd-chain fatty acids were identified from the ovaries of *Cellana toreuma*, and their structures were confirmed by synthesis ([@b1860]). The Australian samples of *Scutus antipodes* afforded scutinin A **173** and scutinin B as epimers **174**-**175** with antibacterial and antifungal properties ([@b0480]). Tetrahydropyrans, which were named as monodontins A and B **176**-**177** exhibiting weak cytotoxicities were reported from the Vietnamese snail *Monodonta labio* ([@b1075]). A bromo-chloro-diterpenoid dolabellol A **178** was identified from *D. auricularia*, and its structure and absolute configuration were confirmed through X-ray diffraction ([@b1320]). The isonitriles, named as pustulosaisonitriles 1-3 **179**-**181** were isolated from *Phyllidiella pustulosa* ([@b2160]). *Spurilla neapolitana* from Bay of Naples afforded cyclohexenyl terpenoid, named as spurillin A **182**, whereas *Spurilla sp.* from Patagonian collection was reported with a farnesol derivative **183** and diterpene spurillin B **184** ([@b0545]). The methylsarcoate analog **185**, 2R secogorgosterol **186**, bisepoxide **187**, isobisglaucumlides B-C **188**-**189** and isosarcophine **190** were isolated from *Phyllodesmium longicirrum* ([@b0250]). A diacylguanidineactinofide **191** with moderately antiproliferative activity was reported from *Actinocyclus papillatus* ([@b0325]), and three ulapualides, C-E **192**-**194** were isolated from the Hawaiian *H. sanguineus* ([@b1610]). *Goniobranchus collingwoodi* was reported to yield spongian-16-one analogs **195**-**200** ([@b0880]), and 6-bromoisatin, and its analogs with anti-inflammatory activities were reported from *Dicathais orbita* ([@b0015]). Chemical investigation of the organic extract of muricid gastropod mollusc, *C. ramosus* reported the presence of cembrane-type diterpenoid **201** with anti-inflammatory and antioxidative properties (Chakraborty, Salas, &Joy, 2020). An antioxidative drimane-type sesquiterpenoid, ramosane **202**, which attenuated the carbolytic and 5-lipoxygenase enzymes, was isolated from *C. ramosus* ([@b0375]). A 16-membered polyether macrocyclic lactone **203** with previously undescribed framework with anti-lipoxygenase and antioxidative potentials were reported from the organic extract of Babylonidae gastropod, *B. spirata* ([@b1805]). A lactonic steroid with an unprecedented 1, 10:8, 9-disecoergostane framework, named as 1, 10:8, 9-disecoergosta-8-en-α-homo-6a-oxa-1-one **204** was identified from a buccinid mollusc, *B. spirata* with anti-inflammatory and carbolytic enzyme inhibition activities ([@b0450]), whereas two unusual Δ^5^ sterols **205**-**206** were reported from *C. ramosus* with anti-inflammatory potencies ([@b1810]). The porostome nudibranch *D. pelseneeri* was reported with 15-acetoxy-ent-pallescensin-A **207**, and dendocarbin-A **208** from its mantle, whereas euryfuran **209** and drimane ester mixture **210** were identified from its internal glands ([@b0910]).

6.3. Bivalve molluscs {#s0045}
---------------------

Bivalves occupied a highest share in the hierarchy of total edible molluscs, although they were not extensively recognized for their pharmaceutical and biomedical properties ([@b1475]). Earlier reports demonstrated that the bivalves possessed numerous compounds ([Fig. 10](#f0050){ref-type="fig"}, [Fig. 11](#f0055){ref-type="fig"} ) with wide-range of bioactive properties ([@b0125]; [@b0405], [@b1510]). A novel sequence of *n*-4 PUFAs **211**-**216** were identified from *Calyptogena phaseoliformis* (deep-sea clam) collected from the Japan Trench ([@b1780]). The hard clam, *M. lusoria* (Taiwan), which was reported with two epidioxysterols **217**-**218** with anticancer properties, was the primary resource of the Chinese antidote for hepatitis and liver illness ([@b1605]). New thio-arsenosugars, **219** and **220** were identified from the extracts of brackishwater clam, *Venus verrucosa* ([@b1545]). Isolation and characterization of *N*-methyl-D-glutamic acid **221** from the Japanese Ark clam, *Scapharca broughtonii* was the first report of this kind of amino acid derivative as natural compound ([@b1980]). The clam, *Callista chione* was reported to contain 1,1′-dimethyl-\[2, 2′\]-bipyridyldiium salt **222**, which was acknowledged for the first time from a natural resource ([@b2090]). The terpenoid constituent from *Tridacna maxima* (giant clam) was found to be germacrene-C **223** ([@b0280]). An arsenic-enclosed sugar sulphate **224** was isolated from *T. maxima*, and was characterized by X-ray crystallography (Edmonds, Francesconi, Healy, & White, 1982). A new antioxidative pigment, chlorophyllone A **225** was isolated from the short-necked clam, *R. philippinarum* ([@b1790]). An arsenic containing nucleoside, 5′-deoxy-5′-dimethylarsinyl-adenosine **226** was isolated from *T. maxima* ([@b0885]). The antioxidant, chlorophyllonic acid A methyl ester **227** was identified from *R. philippinarum* by single crystal X-ray diffraction ([@b2220]). Peridininol-5, 8-furanoxide **228**, 7,8-didehydro-β-cryptoxanthin **229**, peridinin **230**, pyrrhoxanthin 5,8-furanoxide **231**, pyrrhoxanthinol-5, 8-furanoxide **232** and lutein **233** were the main carotenoids found in molluscs ([@b1390], [@b1395]). The 6-epiheteroxanthin **234**, corbiculaxanthin-3′-acetate **235** and corbiculaxanthin **236** isolated from these species were not reported previously from other shellfishes (Maoka, Fujiwara, Hashimoto, & Akimoto, 2005). A series of fucoxanthin **237**-**242** and fucoxanthinol **243**-**244** fatty acid esters were identified from *M. chinensis* (Chinese surf clam) ([@b1400]), *R. philippinarum* and *M. petechialis* ([@b1375]). Amarouciaxanthin A **245** and its ester derivatives were identified from *Paphia amabills* and *P. amabillis* along with C37-skeletal carotenoids **246**-**249** ([@b1380]). The bivalve mollusc, *Codakia orbicularis* was found to be the source of spiro-indolothiazine orbicularisine (Goudou, Petit, Moriou, Gros, Al-Mourabit, 2017).Fig. 10Structures of compounds isolated from bivalve clams. **211**-**216***n*-4 PUFAs, **217**-**218** Epidioxysterols, **219**-**220** Thioarsenosugars, **221***N-*methyl-D-glutamic acid, **222** 1, 1′-Dimethyl-\[2, 2′\]-bipyridyldiium salt, **223** Germacrene-C, **224** Arsenic-enclosed sugar sulfate, **225** Chlorophyllone A, **226** 5′-Deoxy-5′-dimethylarsinyl-adenosine, **227** Chlorophyllonic acid A methyl ester, **228** Peridininol-5, 8-furanoxide, **229** 7, 8-Didehydro-β-cryptoxanthin, **230** Peridinin, **231** Pyrrhoxanthin 5, 8-furanoxide, **232** Pyrrhoxanthinol-5, 8-furanoxide, **233** Lutein, **234** 6-Epiheteroxanthin, **235** Corbiculaxanthin-3′-acetate, **236** Corbiculaxanthin, **237**-**242** Fucoxanthin, **243**-**244** Fucoxanthinol, **245** Amarouciaxanthin A, **246**-**249** Carotenoids, **250** 23-*Gem*-dimethylcholestaenol, **251** Methyl-dihomocholest-5, 22-dienol, **252** 19 (10→5) Abeo-20-methyl-pregnenyl-3-hexenoate, **253** 24^1^, 24^2^-Dihomocholesta-5, 22, 24^1^-trienol, **254** 24^1^-Homocholesta-5, 22-dien-3,24^1^-diol, **255**-**256** 2*H*-Pyranoids, **257** Isopimarane derivative, **258**-**259** Chromenyls, **260**-**262** Aryl polyketides, **263**-**264** Pyranoids, **265**-**266** Isochromenyls, **267**-**268***O*-spirocyclic ether derivatives, **269** Irregular meroterpenoid derivative.Fig. 11Structures of compounds isolated from bivalve mussels and oysters. **270**-**272** Carotenoids, **273**-**274** Bathymodiolamides A-B, **275** 7, 11, 14, 17-Eicosatetraenoic acid, **276** 20-Methyl spirolide G, **277** Chlorosulfolipid, **278**-**282** Azaspiracid analogs, **283** Polychlorinated sulfolipid, **284**-**285** Attenols A-B, **286**-**288** Oxazinins 1-3, **289**-**290** Spirolides B-C, **291**-**292** Mytilin A-B, **293** Apoalloxanthinal, **294** Pinnaic acid, **295** Tauropinnaic acid, **296**-**297** Spirolides E-F, **298**-**299** Dodecahydro-phenanthrenone, **300**-**301** Benzo\[*h*\]naphtho\[1,2-*c*\]chromene derivatives, **302**-**303** Sterols, **304** Ostrerine A, **305**-**312** Carotenoids, **313-314** Crasssostreaxanthin A-B, **315** 3, 5-Dihydroxy-4-methoxybenzylalcohol, **316**-**317** Phenylacetyloxy-trimethylpicene-23-carboxylate derivatives, **318** Spirolide B, **319** Spirolide D, **320** Pectenol, **321** Pectenolone, **322** 4-Hydroxyalloxanthin, **323** 4-Ketoalloxanthin.

The sterol derivatives namely, 23-*gem*-dimethylcholestaenol **250** and methyldihomocholest-5,22-dienol **251** with antioxidative and anti-inflammatory properties were reported from the venerid bivalve clam, *P. malabarica* collected from the south-west coast of Arabian Sea ([@b1170]). Corbiculid clam, *V. cyprinoides* was reported with one abeo-pregnane-type sterol derivative, named as 19 (10→5) abeo-20-methyl-pregnenyl-3-hexenoate **252** along with two cholestenols, 24^1^, 24^2^-dihomocholesta-5, 22, 24^1^-trienol **253** and 24^1^-homocholesta-5, 22-dien-3, 24^1^-diol **254** ([@b1150]). Chemical investigations of organic extract of *P. malabarica* was reported the presence of two 2*H*-pyranoids, in which, one was found to be C18 sesquiterpenoid with prenylated irregular farnesene framework **255**, and another was a C21 prenylated bisabolene-type meroterpenoid, **256** ([@b1130]). The same species was reported for the presence of an isopimarane derivative, which was found to be 18 (4→14), 19 (4→8)-bis-abeo C19 norditerpenoid **257** ([@b1135]), and two chromenyls bearing 3*H*-isochromenone **258** and furanyl-2*H*-chromenyl **259** moieties ([@b1140]). Antioxidative and anti-inflammatory aryl polyketides **260**-**262** were identified from *P. malabarica,* and their proposed biosynthetic pathways assisted by polyketide synthase were used to validate their structural attributions ([@b1145]). These compounds could be the effective substitutes for the commercial synthetic antioxidative food additives for the improvement of shelf-life of foods, and prevention of oxidative stress-induced inflammatory ailments ([@b1145]). The pyranoids **263**-**264** and isochromenyl **265**-**266** class of compounds ([@b1155]), along with oxygenated heterocyclics were classified as *O*-spirocyclic ether derivatives **267**-**268**, and an irregular meroterpenoid derivative **269** were reported from *V. cyprinoides* with antioxidative and anti-inflammatory functionalities ([@b1160]).

Several carotenoids **270**-**272** were isolated from *M. galloprovincialis* collected from the Black Sea of Ukraine ([@b1385]). The bathymodiolamides A **273** and B **274** with antitumor potentials were isolated from a deep-sea mussel, *Bathymodiolus thermophiles* ([@b0045]). An antimicrobial peptide, mytilin-A was purified from the bivalve *M. edulis*, and the peptide analog exhibited potential bioctivity towards marine *Vibrio*, yeasts, and fungi ([@b0490]). A homologous series of *n*-3 PUFAs along with 7, 11, 14, 17-eicosatetraenoic acid **275** were identified as anti-inflammatory components in the New Zealand green-lipped mussel *P. canaliculus* ([@b2010]). The compound, 20-methyl spirolide G **276** was identified from *M. edulis* ([@b0005]). Chromatographic fractionation of *M. galloprovincialis* extracts were found to yield a chlorosulfolipid **277** ([@b0590]). Undescribed azaspiracid analogs **278**-**282** were characterized by tandem mass spectrometric methods from *M. edulis* (Ireland) ([@b1105]). Structure of polychlorinated sulfolipid **283** was reported from *M. galloprovincialis* ([@b0595]) and the spiro-acetals, attenols A **284** and B **285** were isolated from *Pinna attenuate* ([@b1975]). New bioactive alkaloids, oxazinins 1-3 **286**-**288** were identified from *M. galloprovincialis* ([@b0600]). The macrolides, spirolides B-C **289**-**290** were isolated from *M. edilis* ([@b1065]), and the mycosporine derivatives, such as mytilin A **291** and B **292** were acquired from *M. galloprovincialis* ([@b0530]). The apocarotenoid, apoalloxanthinal **293** was isolated from *M. coruscus* ([@b1370]), and cytosolic phospholipase A2 inhibitors, pinnaic acid **294** and tauropinnaic acid **295** were isolated from *P. muricata* ([@b0540]). Spirolides E **296** and F **297** metabolites from *M. edulis* could help defining the characteristic structural features of this class of compounds ([@b1060]). Two dodecahydro-phenanthrenone derivatives **298**-**299**, benzo\[*h*\]naphtho\[1,2-*c*\]chromene derivatives **300**-**301**, and two sterol analogs **302**-**303** were isolated from the Asian green mussel, *P. viridis*. Among these, the compounds with chromene-16-carbaldehyde and chromen-12-one **300**-**301** functionalities displayed potential anti-inflammatory activities ([@b0445]).

Ostrerine A **304** was reported from *O. rivularis*, and was used as foodstuff and conventional Chinese medication ([@b1590]). The carotenoids **305**-**307** were reported from *C. gigas* (Japan) (Maoka, Fujiwara, Hashimoto, & Akimoto, 2005), whereas an antimicrobial peptide, defensin (molecular weight of 4265 Da) was isolated from the oyster, *C. virginica* ([@b1850]). The carotenoids **308**-**312** were reported from *C. gigas* ([@b1405]). Metabolites of fucoxanthin, crasssostreaxanthin A **313** and crassostreaxanthin B **314** ([@b0900]), along with C37-skeletal carotenoids were identified from the mollusc *C. gigas* (Maoka, Fujiwara, Hashimoto, & Akimoto, 2005). A polyphenolic compound, 3, 5-dihydroxy-4-methoxybenzyl alcohol **315** was identified from the Pacific edible oyster (*C. gigas*), and its potential antioxidant activity was determined ([@b2135]). Chemical investigations of the solvent extract of *C. madrasensis* reported two phenylacetyloxy-trimethylpicene-23-carboxylate **316**-**317** derivatives with potential anti-inflammatory and antioxidant activities ([@b0370]). The macrolides, spirolides B **318** and D **319** were reported from a scallop, *Placopecten magellanicus* ([@b1065]), whereas spirolides E and F were isolated from the scallop *P. magellanicus* ([@b1060]). Metabolites of alloxanthin and diatoxanthin, such as pectenol **320**, pectenolone **321**, 4-hydroxyalloxanthin **322** and 4-ketoalloxanthin **323** were reported from the scallops ([@b0830]).

7. Chemical classification of secondary metabolites from molluscs of marine and estuarine origin {#s0050}
================================================================================================

Marine and estuarine molluscs were endowed with varying classes of organic compounds classified under different categories, particularly as sterols, terpenes, alkaloids, peptides, polypropionates, fatty acids etc. with potential pharmacological properties ([@b0770], [@b0775], [@b0780], [@b0785], [@b0790], [@b0795], [@b0800], [@b0805], [@b0810], [@b0815], [@b0820], [@b0825], [@b0830], [@b0215], [@b0220], [@b0225], [@b0230]; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2015; 2016; 2017; 2018; [@b0355]). The comparison of chemical diversity of the major types of secondary metabolites from the bivalves and gastropods were shown in [Fig. 12](#f0060){ref-type="fig"} . In gastropods, the terpene class of compounds were dominated by 55 % and the sterols were least reported of about 3 % ([@b0125]). However, the sterols were found to occupy the major share of about 41 % in bivalves, whereas the terpenes were found to be least reported of about 5 % ([@b0125]). Terpenes were the major area of research of gastropods, which might be attained through their diet for use against defense mechanisms ([@b1915]). Greater number of sterols in the bivalve molluscs might be due to the biochemical changes in their reproductive pathways ([@b0125]). Comparatively large numbers of alkaloids (5-6 %) and polyproprionates (13-32 %) were reported from the molluscs, whereas nitrogenous compounds were relatively rare ([@b0125]). Extensive reports of secondary metabolites were detailed under each class of molluscs, and herein we have represented some of the important organic classes of molluscan metabolites.Fig. 12Relative proportion of the various chemical classes of secondary metabolites isolated from (**A**) gastropods and (**B**) bivalves over the period 2000 to 2019 (compiled from [@b0830] to 2002; [@b0215] to 2018; [@b0355], [@b0125]).

7.1. Terpenes {#s0055}
-------------

Marine and estuarine molluscs were described to produce a wide array of variants of intereseting terpenoid metabolites, which were mainly classified under chamigrene, amphilectane, cembrane with unusual functionalities, including groups like isothiocyanates, dichloroimines, isonitriles, isocyanates, halogens ([@b1005]). The terpenoids from marine molluscs were reviewed from 1984s, in the marine natural products ([@b0770], [@b0775], [@b0780], [@b0785], [@b0790], [@b0795], [@b0800], [@b0805], [@b0810], [@b0815], [@b0820], [@b0825], [@b0830], [@b0215], [@b0220], [@b0225], [@b0230]; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2015; 2016; 2017; 2018; [@b0355]). In most of the cases, the chemical defenses by utilizing the terpenoids might be failed to prevent the feeding by certain predators ([@b1005]). The mollusc, *A. dactylomela* was known to produce different structural types of terpenes, and these terpenoids were produced through their algal diet ([@b2150]). Comprehensive biosynthetic analyses of terpenoids from the marine molluscs were previously carried out ([@b1005]). The studies demonstrated that the mollusc produces terpenes not only from their diet, but also by the *de novo* biosynthesis, which includes the degraded sesterterpenes from the mevalonic acid pathway (Fontana et al., 2003a; Fontana et al., 2003b; [@b0935]). Biogenesis of diterpenoid glycerides, verrucosins from mollusc *D. verrucosa*, and detailed terpene biosynthesis in *Doriopsilla areolate* were previously reported ([@b0530], [@b1370]). The European nudibranch *D. areolate* was characterized by a series of defensive sesquiterpenoids, related to drimane and ent-pallescensin A ([@b0300]). The strucrtures were unique for these opisthobranch molluscs, even though the basic skeletons of these drimane and ent-pallescensin were also reported from sponge, *Dysidea* suggesting that the molluscs and the sponge represented the prey-predator pair ([@b0300]). Sesquiterpenes, ascobullins A-B were reported from *A. ulla* (Gavagnin, Mollo, & Montanaro, 2000), and the anti-inflammatory oxygenated terpenoids classified under furano-norditerpenoid, sesquiterpenoid and diterpenoid were reported from *U. duvaucelii* ([@b0470]). A drimane sesquiterpenoid was isolated from *C. ramosus* ([@b0375]), C19 norditerpenoid, isopimarane derivative was described from *P. malabarica* ([@b1135]), and an irregular meroterpenoid was isolated from *V. cyprinoides* ([@b1160]), with 5-lipoxygenase inhibitory effects. The pyranoid enclosed irregularly prenylated farnesene compound and C21 prenylated bisabolene-type meroterpenoid were also described from *P. malabarica* ([@b1130]).

7.2. Sterols {#s0060}
------------

Sterols are bioactive lipid analogues, and were found to be the main constituents of all marine molluscs, particularly in the bivalve molluscs ([@b0125]; [@b0970]). Diverse structural skeletons of steroids were found to exhibit interesting therapeutic properties, such as anti-inflammatory, inhibition of DNA synthesis, immunological effects, cytotoxicity, and other antagonistic activities ([@b0970], [@b0965]). These significant classes of compounds were described to possess the ability to cross the lipophilic cell membrane, and binds to the steroid receptors to exhibit their complete physiological functionalities ([@b1945]). It was described that the steroids could be biosynthesized in the marine molluscs under unusual ecological surroundings, and was found to be active as self-protective strategies against the invaders ([@b2275]). Among different types of steroids, such as polyoxygenated tetracyclic nucleus with various degrees of unsaturation, steroids with spiro A/B ring system, steroidal alkaloids, atypical side chain substitution, 3*β*-cholestane esters, steroid-amino acid conjugates, seco-steroids, and bicyclo\[4.4.1\]/bicyclo\[4.3.1\] A/B steroids were reported from various mollusc species ([@b1870]). Anti-inflammatory properties of the di-unsaturated C-27 polyhydroxy sterols against pro-inflammatory cyclooxygenases/cytokines were reported from the gastropod, *Trimusculus peruvianus* ([@b0720]). Ketosteroids were isolated from a marine prosobranch mollusc *Onchidiopsis variegate* ([@b1820]), and an anti-inflammatory lactonic steroid with 1, 10:8, 9-disecoergostane framework was described from *B. spirata* ([@b0450]). Two unusual Δ^5^ sterols, (5*Z*)-24a-homocholesta-5, 24a^1^(24a^2^)-dien-3-ol, 27(25→23)-abeo-(5*Z*)-3-hydroxy-24-isopropyl cholesteno-26, 23-lactone from *C. ramosus* ([@b0450]), 23-*gem*-dimethylcholesta-5-en-3*β*-ol and (22*E*)-24^1^, 24^2^-methyldihomocholest-5, 22-dien-3*β*-ol from *P. malabarica* ([@b1170]) along with abeo-pregnane-type sterol derivative and polyhydroxylated cholestenols from *V. cyprinoides* were reported previously ([@b1150]). A progesterone homolog was purified from the dorid nudibranch *Aldisas maragdina* ([@b0215]). A variety of uncommon Δ^8^ unsaturated methyl and dimethyl sterols were obtained from the Japanese limpet *C. grata* and *C. toreuma* ([@b0190]), whereas 9,11-secosteroid aplysiasecosterol A, along with two novel secosterols were isolated from *A. kurodai* ([@b0170]).

7.3. Alkaloids {#s0065}
--------------

The number of identified molluscan alkaloids was interestingly increased in the recent years due to their promising biological activities. Alkaloids represented a structurally different class of secondary metabolites, and the occurrence of nitrogen was attributed for their bioactivities ([@b1535]). Several alkaloids were isolated from *O. rivularis*, to treat tuberculosis, dizziness, and to reduce inflammation ([@b1590]). [@b1210] reported the alkaloids, named as neoaplaminone sulfate, neoaplaminone, and aplaminone with cyctotoxic properties from the mollusc, *A. kurodai*. Two new alkaloids, halgerdamine and C^2^-*α*-D-mannosylpyranosyl-L-tryptophan were described from *Halgerda aurantiomaculata* ([@b0745]). The uncommon 1,2,4-oxadiazole skeleton enclosed phidianidines A-B were isolated from *Phidiana militaris* with cytotoxicity against several tumor cells ([@b0340]). Phidianidine A was reported as a newer chemokine receptor ligand, which inhibited C-X-C motif chemokine 12-induced DNA synthesis, and cell migration ([@b0340]). The first ergot peptide alkaloid ergosinine, which was found to play defensive role in marine molluscs, was reported from *P. forskalii* ([@b2125]). DOPA-(2-amino-3-(3',4'-dihydroxyphenyl)propionic acid) derived pyrrole alkaloids, lamellarins were first isolated from the mollusc, *Lamellaria sp.* ([@b0040]). Thereafter, more than seventy lamellarin derivatives and pyrrole-derived alkaloids were reported ([@b0760]). The 3,4-diarylated pyrrole 2-carboxylic acid ester or amide functionality was found to be major structural subunit of lamellarins. Most of the lamellarins, lukianols, polycitrins, polycitones, storniamides, and ningalins possess a common structural subunit, and were predominantly isolated from the marine prosobranch molluscs (Cantrell, Groweiss, Gustafson,& Boyd, 1999). These secondary metabolites were reported to exhibit potential bioactivities, such as cytotoxicity ([@b0320]), antitumor ([@b0350], [@b1720]), reversal of multidrug resistance ([@b0255]), antibiotic ([@b1600]), and antioxidant ([@b1245]) properties.

7.4. Polypropionates {#s0070}
--------------------

During the last thirty years, several structurally-diverse polypropionate metabolites were reported from the marine molluscs ([@b0690]). Most of the marine polypropionates were reported for their pharmacological potentials, such as cytotoxicity, antimicrobial, antifungal, antibiotic and antiviral properties ([@b0690]). However, there were other polypropionates that were interrelated with their ecological systems, with no pharmacological effects ([@b0690]). These typical metabolites of molluscs were derived through the condensation of several propionate units ([@b0690]). The acyclic polypropionates, siphonarienal (aldehyde) ([@b1555]), siphonarienone, siphonarienedione, and siphonarienolone ([@b1550]) were reported from an opisthobranch gastropod, *S. grisea*, whereas norsiphonarienone and isosiphonarienolone were described from *S. pectinata* ([@b1620]). An acyclic polypropionate, aglajne-1 was isolated from *B. occidentalis*, which was regarded as chemical-taxonomic marker for marine molluscs in the genus *Bulla*. This compound was reported to exhibit significant antibacterial potentials against *Escherichia coli*, *Serratia marcescens*, *Staphylococcus aureus* and *Pseudomona aeruginosa* ([@b0080]). Furanone containing compound, aglajne-2 was isolated from *Aglaja depicta* and *B. striata* ([@b0615]). Two families of ascoglossan molluscs, Stiligeridae and Polybranchiidae were reported as potential sources of polypropionates ([@b0690]). The 2-pyrone polypropionates were reported from *Cyerce nigricans* ([@b1750]), *A. depicta* (aglajne-3), and *Navanax inermis* (5,6-dehydroaglajne-3) ([@b0615], [@b1900]). The 4-pyrone polypropionates were reported from ascoglossan molluscs, *C. nigricans*, *C. cristallina* and *Ercolania funerea*, in which cyercenes A-B were isolated from *C. cristallina* ([@b2105]), and 12-norcyercene B, 7-methylcyercene B, and 7-methyl-12-norcyercene B were reported from *E. funera* ([@b2110]). Hemiacetal ring enclosed marine polypropionates were reported from *Siphonaria australis* ([@b1950]) and *S. denticulata* (compounds named as denticulatins A-B) ([@b1045]). An unusual 2, 4, 6-trioxaadamantane ring framework enclosed polypropionate, named as muamvatin was reported from *S. normalis* ([@b1740]). The polypropionates isolated from the skin of *P. membranaceus* along with the acid secretion were found to bear significant functional role in their chemical defense strategies ([@b0570]). Overall, the polypropionates exhibited pronounced pharmacological potencies along with their ecological effects ([@b0690]).

7.5. Peptides {#s0075}
-------------

Peptides are significant class of secondary metabolites with wide spectrum of therapeutic, and nutraceutical pluralities ([@b0515]). Molluscs were occupied with a predominant share in the production of peptides with bioactive pluralities ([@b0515]) exhibiting cardioprotective, antiviral, anticancer, antioxidative, antimicrobial, analgesic, antidiabetic along with neuroprotective properties. Therefore, this class of chemistry attracted the attention in functional food and pharmaceutical fields for use against several diseases ([@b0515]). Some of the peptides have higher commercial values, whereas few of them were commercialized in the markets, or in the clinical and preclinical pipelines ([@b0515]). An important amino acid peptide, ziconotide (25 amino acid peptide with three disulfide bonds) from *C. magus* was reported to possess potential analgesic property, which was found to be 1000 times potent than morphine in the animal models of nociceptic pain ([@b1575]). Cone snails were considered as valuable resources of active peptides, called as conotoxins, which consisted of mixture of peptides with short chains of disulfide amino acids ([@b1520]). Earlier studies postulated that the peptides were effective in the treatment of cancer ([@b1855]). A linear pentapeptide, dolastatin 10 and depsipeptide dolastatin 15 with promising antiproliferative activities were reported ([@b1650]). Dursatellanin-P with 60-kDa protein was isolated from the purple ink of *B. leachii* with anti-HIV activity ([@b1695]). The cyclic hexapeptide keenamide A, and dehydroamino-butyric acid-containing peptide, kahalalide possessing potential antitumor activities F were reported ([@b0905], [@b2155]).

7.6. Macrolides {#s0080}
---------------

Macrocyclic ethers or lactones are cyclic systems with more than ten carbon atoms enclosing ether, ester or ketone groups. These were considered as the significant sources of pharmaceutical medications and nutraceuticals with multiple bio-potentials, such as antitumor, antibacterial and antimalarial etc. ([@b0775]). Previous studies reported the presence of natural macrocycles with more than fifty atoms in the ring system, even though 14-, 15-, 16-membered macrocycles commonly occurr in nature ([@b0175]). Since the macrocycles were not rigid, they could easily interact with the dynamic protein targets, and thus exhibited potent bioactivities ([@b1080]). Macrocyclic lactones or polyethers of molluscan origin were found to possess potent anticancer pluralities ([@b1080]). The macrocyclic compound, aplyronine and its derivatives, aplyronines B-C were reported from *A. kurodai*, with potent antitumor effects (Yamada, Ojika, Ishigaki, & Yoshida, 1993). Similarly, ichthyotoxic macrolides, aplyolides B-E were found from *A. depilans* ([@b0815]). Stereochemistry of macrocyclic metabolite, ulapualide A from *H. sanguineus* was recognized by total synthesis as predicted by molecular mechanistic analyses of the metal chelate ([@b0800]). The cephalopod, *A. neglectus* was reported to contain four macrocyclic lactones of 7-hydroxy-5-methyl-1,4-dioxecan-10-one, furo\[1,4,8\]trioxacyclohexadecine-12,19-dione, octahydro-benzo\[1,15\]dioxacyclotridecin-2-one and 7-ethyl-octahydro-11-hydroxy-2-oxobenzo\[1,12\] dioxecine with cardioprotective properties ([@b0465]). A 16-membered polyether macrocyclic lactone was reported from *B. spirata* with anti-inflammatory potential ([@b1805]).

7.7. Fatty acids {#s0085}
----------------

Lipids and fatty acids, which were found to be essential for the formation of membrane structures, and their metabolic activities, were the key pre-structures of biological membranes of molluscs ([@b1010]). DHA and EPA were the predominant fatty acids, which were provided by the dinoflagellates and diatoms, respectively, were ubiquitous in the molluscs of marine origin. The diet components and feeding mechanism were the key factors to cause changes in the type, and amount of fatty acid production in molluscs ([@b1010]). For example, the diet of filter feeder bivalves includes dinoflagellates, and reported to possess higher level of DHA ([@b1085]), whereas the detritus feeder molluscs were reported higher levels of saturated and mono-unsaturated fatty acid profiles ([@b1110]). Variation in polyunsaturated levels in the molluscs might be due to the transport of fatty acids to their reproductive organs for development of gonad. For example, winter is the reproductive time of molluscs, and therefore, the fatty acid level could be lower in this season ([@b0110]). Also, temperature, metabolic rate, physiological activities, and food availability could significantly affect their fatty acid production ([@b0110]). Fatty acids, neutral lipids, phospholipids, odd-numbered fatty acids and C20 polyunsaturated fatty acids were previously reported from different parts of molluscan fractions ([@b0135]). Derivatives of fatty acids along with other secondary metabolites were characterized from the sea hare *A. kurodai* ([@b0125]). Previous reports suggested that palmitoleic, oleic, linoleic and arachidonic acids from molluscs possessed potential antimicrobial properties against the human pathogens ([@b0135]). Overall, the fatty acids might contribute towards the cell membrane maintenance, antimicrobial activity along with the reproductive cycle of molluscs ([@b0135]). A polyunsatrated fatty acid, namely heneicosa-5, 8, 11, 14-tetraenoic acid was reported as a novel natural product from the mollusc, *S. lignarius* ([@b0185]).

7.8. Miscellaneous {#s0090}
------------------

Compounds with mixed biosynthetic origin do not fall into any class of organic chemistry, which were described herein. The alarm pheromones, named as alkyl phenols from the bubble snail *Haminoea callidegenita* ([@b0825]) and an unusual chlorinated pyrrolidone *Asteronotus cespitosus* ([@b0185]), were classified as mcellaneous metabolites. A diacylguanidine, limaciamine was obtained from *Limacia clavigera* ([@b0825]). The metabolite, aplysiaviolin from *Aplysia parvula* ([@b0185]) and a *trans*-decalin from the limpet, *Trimusculus reticulatus* ([@b0230]), were reported. Antimicrobial brominated indoles, along with indolequinones were reported from *Drupella fragum* ([@b0825]). A series of malyngamide metabolites with mild cytotoxicity and anti-inflammatory potencies were reported from *B. leachii* ([@b0230]). C15-halogenated compounds, and dihydrocaulerpenynes from *A. dactylomela* and *E. expansa*, respectively were classified herein ([@b0825]). The polyol, durinskiol A from *Chelidonura fulvipunctata*, mycosporine-like amino acids, aplysiapalythine A-C from *A. californica*, cytotoxic isonitrile-containing lipid, actisonitrile from *A. papillatus*, phorboxazole related metabolites from the Indian nudibranch, *Aldisa andersoni* were also classified as miscellaneous ([@b0230]; 2007; 2008; 2009; 2010; 2013; 2014; 2015; 2016; 2017; 2018). Chromenoids/isochromenoids from *S. inermis* ([@b1255], [@b1260]), isochromenone/furano-chromene derivatives from *P. malabarica* ([@b1130]) and pyranoids/isochromenoids/spirocyclic ethers from *V. cyprinoides* ([@b1160], [@b1155]) with anti-inflammatory, antioxidative, antihyperglycemic potentials were previously described.

8. Pharmacodynamic studies and therapeutic applications of marine and estuarine molluscs {#s0095}
========================================================================================

The unfavorable living conditions and the defensive mechanisms of the marine or estuarine molluscs were found to poduce compounds with pharmacological potentials against various diseases ([Table 5](#t0025){ref-type="table"} ). Comparison of number of reports on various pharmacological properties of major molluscan species, such as *Halitis diversicolor*, *H. discus*, *B. spirata*, *Babylonia zeylanica*, *Bursa spinosa*, *C. ramosus*, *P. malabarica*, *V. cyprinoides*, *M. meretrix*, *P. viridis*, *P. canaliculus*, *C. madrasensis*, *L. duvauceli* (*U. duvauceli*), *C. indicus*, *S. pharaonis*, *S. inermis* and *A. marginatus* (retrieved from the GoogleScholar excluding citations and patents, accessed on 12/10/2019) were illustrated in [Fig. 13](#f0065){ref-type="fig"} . These reports were described that about 23 % of pharmacological properies were exhibited by *H. discus* followed by *P. viridis* (20 %), *M. meretrix* (15 %), *H. diversicolor* (12 %), and *P. canaliculus* (9 %), in the descending order.Table 5Pharmaceutical potentials of prominent members of molluscan species against various diseases**Studied molluscCommon nameBioactivitiesReferences***Arca subcrenata*Ark clamAnti-inflammatory activity by inhibition of NO generation in LPS-stimulated RAW264.7, reduced production of IL-8, inhibition of COX-2 and iNOS pathwaysWu, Hu, Song, & Zhu, 2014*Bellamya bengalensis*SnailAnti-inflammatory activity by inhibition of ROS, TNF-*α* and NO generation, inhibition of NFκ*β* translocation[@b0145]*Buccinulum corneum*SnailAntiviral activity against human T-cell leukemia virus-1[@b1585]*Crenomytilus grayanus*MusselAntiviral activity against HIV virus[@b1315]*Perna canaliculus*New Zealand green-lipped musselAntioxidant, anti-inflammatory activity by inhibition of PGE~2~ generation, inhibition of lipoxygenase, antihypercholesterolemia, TNF-*α* and PGE biosynthesis, inhibition of TNF-*α* and IL-1 generation, inhibition of COX-1 and COX-2Tiffany & Bui, 2002; [@b1015]*Aplysia fasciata Aplysia punctate*Sea hareReduction in NO concentration, anti-inflammatory activity by inhibition of LOX[@b1630]*Mytilus unguiculatus*MusselAnti-inflammatory activity, reduction in swelling associated with paw edema, suppression of inflammatory mediators and proinflammatory cytokines[@b1205]*Paphia malabarica*ClamAntioxidant activities against free radicals, antiinflammatory activity against COX-1, COX-2 and 5-LOX, antidiabetic activities, ACE-1 inhibition[@b1125]*Sepia officinalis*Cuttle fishInhibition of acetic acid-induced writhing, increase in latency period of mice in hotplate[@b0750]*Sepia pharaonis*CuttlefishAnti-inflammatory activity, reduction in carrageenan-induced and formalin-induced paw edema, ACE-1 inhibitory activity[@b1115], [@b0455]*Coelatura aegyptiaca*MusselReduction in paw licking, slight increase in latency time of mice in hotplate[@b0750]*Perna viridis*Green musselAnti-inflammatory, reduced histamine-induced edema, significant reduction in carrageenan-induced edema, inhibition of dextran-induced paw edema, antioxidant[@b0410], [@b0405]*Rapana venosa*WhelkRespiratory syncytial virus, Antiviral activity against Herpes[@b1530], [@b0730]*Haliotis discus*AbaloneInhibition of NO production in RAW264.7, reduction in TNF-*α* and IL-6 concentration, suppression of NO production through iNOS, reduction in TNF-*α* , IL-6 generation[@b1120]*Cistopus indicus*OctopusAntiinflammatory activity against COX-1, COX-2 and 5-LOX, antidiabetic activities against *α*-amylase and DPP-4[@b0460]*Babylonia spirata*GastropodAntioxidant, anti-inflammatory, antidiabetic activitiesSalas, & Chakraborty, 2020*Chicoreus ramosus*GastropodAntioxidant activities against free radicals, antiinflammatory activity against COX-1, COX-2 and 5-LOX, antidiabetic activitiesSalas, & Chakraborty, 2020*Haliotis diversicolor*AbaloneAnti-inflammatory activity by reduction in iNOS manifestation, augmentation of macrophage function[@b0505]*Villorita cyprinoides*ClamAntiinflammatory activity against COX-2[@b1155]*Haliotis laevigata Haliotis rubra*AbaloneAntiviral activity against Herpes[@b0680]*Littorina littorea*PeriwinkleAntiviral activity against Herpes[@b0700]*Helix lucorum*SnailAntiviral activity against Epstein-Barr virus[@b2240]*Sepia inermis*CuttlefishACE-1 inhibitory activity, antidiabetic activities of inhibition of α-amylase and dipeptidyl peptidase 4 enzymes[@b1250]*Mercenaria mercenaria*ClamAntiviral activity against leukaemia viruses[@b1175]*Crassostrea madrasensis*Oyster*In vitro* anti-inflammatory activities against COX-2, 5-LOX, antihypercholesterolemic activity against HMGCR, anti-hypertensive activity against ACE-1, antidiabetic effects against *α*-amylase, *α*-glucosidase, DPP-4, free radical inhibition[@b1250]*Crassostrea gigas Crassostrea rhizophorae*OysterAntiviral against Herpes, infectious pancreatic necrosis virus, human adenovirus Antiviral activity against Herpes, human adenovirus[@b0345], [@b1675]*Amphioctopus marginatus*OctopusAntioxidant activity, antihypertensive activity against ACE-1, inhibition of HMGCR[@b1250]*Uroteuthis duvaucelii*Loligo*In vitro* anti-inflammatory activities against COX-2, 5-LOX, antihypercholesterolemic activity against HMGCR, anti-hypertensive activity against ACE-1, antidiabetic effects against *α*-amylase, *α*-glucosidase, DPP-4, free radical inhibition[@b1250][^9]Fig. 13Comparison of number of reports on various pharmacological properties of major mollusc species (retrieved from GoogleScholar excluding citations and patents, accessed on 12/10/2019).

8.1. Antioxidant activity {#s0100}
-------------------------

Several molluscs were reported for their various antioxidant pluralities. Polysaccharides from *Mactra chinensis* were reported to possess scavenging activities against hydroxyl and superoxide anion free radicals ([@b1300]). Aqueous and alcoholic extract of *M. veneriformis* showed *in vitro* antioxidant potentials (Luan, Wang, Wu, & Jin, 2011). It was stated that the presence of hydrophilic/lipophilic antioxidant components like polyunsaturated fatty acids, amino acids and carotenoids were accountable for the functional food and therapeutic potentials of the molluscs (Luan, Wang, Wu, & Jin, 2011). There were reports for the occurrence of antioxidants in molluscs that could constrain the cell damages from oxidative reactions ([@b1510]). Abalone (gastropod mollusc) extracts were reported to possess prospective antioxidant and anti-coagulant properties ([@b1225]). Dose-dependent antioxidant responses of the methanolic extracts of *P. malabarica* and its lipid peroxidation inhibition potentials against the reactive oxygen species were reported in an earlier study ([@b1625]). Studies on bivalve mollusc, *P. viridis* highlighted the potential antioxidant activities related to the free radical inhibition, and lipid peroxidation, and thus suggested its utilities as prospective health food ([@b0420]). The enzymatically obtained gelatin hydrolysate of flying squid displayed potent antioxidant ability through 2, 2-diphenyl-1-picrylhydrazyl (DPPH) radical quenching mechanism at the concentrations of 16 and 12 mg/mL. This inhibotry activity was found to superior than the synthetic antioxidants like butylated hydroxyanisole and *α*-tocopherol. This was found to contain antioxidant amino acids, such as histidine, proline, tyrosine, leucine and alanine ([@b1925]). The studies showed that the hydrolysate with molecular weight of 383-1492 Da and the presence of aromatic and hydrophobic amino acids, were considered as the predominant reasons for its potential antioxidant activities. Hydrophobicity of the compounds was reported to play a significant role for their antioxidant properties owing to an increased accessibility to the hydrophobic target sites ([@b1925]). *In vitro* antioxidant property of *P. viridis* was ascribed to the presence of phenolic compounds that could act as hydrogen or electron donors. The abilities to delocalize the unpaired electrons, and the chelation of metal ions were attributed by their antioxidant potentials ([@b1905]).

The antioxidant potencies of the crude extracts of cephalopods, such as *S. pharaonis*, *U. duvaucelii*, *C. indicus*, *S. inermis* and *A. marginatus* were previously reported ([@b0365], [@b0460]). These established that the greater total phenolic contents in molluscs might play an important role in inhibiting the free radicals, and the total phenolic contents were positively correlated with their antioxidant activities ([@b0460], [@b1480]). Potential radical scavenging activities of *C. indicus* and *S. inermis* might be due to the presence of substituted oligosaccharide fractions with hydroxyl groups and unsaturations. These could effectively donate the protons to the free radical by hydrogen atom transfer mechanism ([@b0460]). Methanol and ethyl acetate tissue extracts of *Littorina littorea* (Borquaye, Darko, Oklu, Anson-Yevu, & Ababio, 2016) and the ink extract of *S. officinalis* displayed antioxidant potentials ([@b1890]). Antioxidant potentials of tissues and ink extracts of the cephalopods were detailed in a previous report of literature ([@b0535]). The historical seafood, *M. meretrix* was found to harbor antioxidant pluralities ([@b2140]). Aqueous and ethanolic extracts of New Zealand surf clams, *Crassula aequilatera*, *Mactra murchisoni*, and *Paphies donacina* were found to possess potential antioxidant properties ([@b1565]). Bioactive components, such as peptides, proteins, and enzyme inhibitors identified from *M. meretrix* exhibited antineoplastic and antioxidant effects ([@b1070], [@b2255]). [@b0435] studied the effect of natural additives on fatty acid signatures of *P. viridis* in time-dependent accelerated shelf-life study, and studied the antioxidative status of a nutrient enriched formulation through a shelf-life study ([@b0410]).

8.2. Anti-inflammatory activity {#s0105}
-------------------------------

Extract of the Australian muricid gastropod, *D. orbita* was found to exhibit nutraceutical functionalities and anti-inflammatory properties through inhibition of prostaglandin E~2~ (PGE~2~), tumor necrosis factor alpha (TNF*α*), and nuclear factor kappa-*β* (Ahmad et al., 201). Higher C~20~-C~22~ *n*-3 fatty acid contents present in the cephalopod species were found to be accountable for their anti-inflammatory activities ([@b1770]). Ink extract of *S. officinalis* displayed anti-inflammatory potentials ([@b1890]). Anti-inflammatory activity of mussel, *Coelatura aegyptiaca* was evaluated by [@b0750], whereas the methanol, ethanol, and aqueous extracts of *P. viridis* exhibited anti-inflammatory properties in different *in vivo* models ([@b1910]). Earlier studies of freeze-dried extract of New Zealand green-lipped mussel *P. canaliculus* exhibited the capacity to prevent the induced inflammation. It could act as dual inhibitors of membrane arachidonic acid oxygenation by cyclooxygenases and lipoxygenase mechanisms, thereby decreasing the synthesis of prostaglandin, and leukotriene along with the down-regulation of inflammatory pathways ([@b0155]). C~20~-C~22~ *n*-3 PUFAs, namely EPA and DHA were regarded as the precursors of anti-inflammatory resolvins, E- and D-series, which were found to be higher in *P. viridis* ([@b0025]). The bivalve mollusc, *P. canaliculus* was used against osteoarthritis and rheumatoid arthritis ([@b1455]). The Asian green mussel *P. viridis* was found to exhibit potent *in vitro*/*in vivo* anti-inflammatory effects (Chakraborty et al., 2012), wherein the role of green mussel extract supplemented with natural antioxidant additives on inflammatory prostaglandins, PGE~2~/PGF~2~ *~α~* and C20 *n*-6 fatty acid were studied through accelerated shelf-life study. This study highlighted the use of PGE~2~ and PGF~2~ *~α~* analyses as an index of lipid peroxidation, and antioxidant potentials ([@b0405]; Chakraborty et al., 2012). Carrageenan-induced edema model was used to check the efficacies of green-lipped mussel extract, which was showed significant relief from foot-pad edema in rats ([@b1205]). The arthritic rats were effectively cured by furan-fatty acids obtained from the green-lipped mussel ([@b2120]). The Okinawan mollusc, *Pinna muricata* was reported for Ca^2+^ channel activation, and was found to possesses anti-inflammatory properties ([@b1505]). Aryl polyketides isolated from *P. malabarica* exhibited greater anti-inflammatory properties against 5-lipoxygenase enzyme (IC~50~ 0.76-0.81 mg/mL), when compared to the standards, sodium salicylate (IC~50~ 1.75 mg/mL) and ibuprofen (IC~50~ 0.93 mg/mL) ([@b1140]). The 1*H*-benzochromenone compound from *C. ramosus* exhibited greater inhibitory activity against 5-lipoxygenase enzyme (IC~50~ 2.12 mM), when compared to the standard ([@b0385], [@b0380]). A polysaccharide, namely glycosaminoglycan-xylopyranan from *B. spirata* was reported to attenuate pro-inflammatory 5-lipoxygenase (Chakraborty & Salas, 2019c). Anti-inflammatory 2*H*‐chromenyl derivatives were isolated from the organic extract of *B. spirata* ([@b0390]). A polygalactosamino-glucopyranosyl fucopyranose isolated from C*. madrasensis* exhibited prospective anti-inflammatory activities against pro-inflammatory enzymes COX-2 and 5-LOX (IC~50~ ≤ 0.15 mg mL^-1^). Quantitative real-time polymerase chain reaction displayed that the polygalacatan suppressed the mRNA of nuclear factor-*κ*B and COX-2 in lipopolysaccharide-induced macrophages ([@b0395]).

8.3. Antihypertensive activity {#s0110}
------------------------------

Consumption of molluscs and its related products were reported with a number of health benefits, particularly as antihypertensive agents. For example, noteworthy reductions in the pathophysiologies related to hypertension were found to be associated with the consumption of blue mussels and oysters due to the occurrences of biologically active peptides ([@b2175]). The trypsinized hydrolysate peptide with the sequence of Trp-Pro-Met-Gly-Phe (molecular weight of 636.75 Da), which was described from the clam, *Cyclina sinensis* was reported for antihypertensive activity against angiotensin converting enzyme (ACE) in a competitive manner with an IC~50~ value of 0.789 mM ([@b2235]). This studied peptide, which has hydrophobic amino acid residues at C-terminus, and N-terminus, was considered as the significant characteristic for prospective ACE inhibitory activity ([@b2235]). Its molecular docking simulation inferred that this peptide could bind to active site of ACE, and the conformation of pentapeptide-ACE complex was stable ([@b2235]). A macrocyclic lactone with furo\[1,4,8\]trioxacyclohexadecine-12,19-dione from *A. neglectus* was reported to exhibit potent *in vitro* ACE inhibition with IC~50~ of 1.12 mM, wherein its *ex-vivo* analyses revealed its protecting effects against angiotensin-II induced cardiac hypertrophy on H9C2 cells at 25 μg/mL ([@b0465]). The latter study found around 34 % decrease in the cell area, together with increase in viability attributed to its antihypertrophic effects and enhanced regeneration of cardiomycetes ([@b0465]). A noteworthy reduction of about 86.8 % in cellular size of H9C2 cells upon macrocyclic lactone treatment, appropriately confirmed its potentials to inhibit ACE-II induced cardiac hypertrophy ([@b1670]). *In vitro* antihypertensive properties of the organic extracts of *S. pharaonis*, *U. duvaucelii*, *C. indicus*, *S. inermis* and *A. marginatus* were studied using the proton-nuclear magnetic resonance spectroscopic techniques ([@b0460]). Antihypertensive components were reported from the squids, cuttlefish, and octopus ([@b0115]). The muscle protein hydrolysates of mollusc were reported for antihypertensive potentials against ACE-I ([@b2015]). Antihypertensive peptides from *Mytilus coruscus* was reported in the earlier literature of [@b2195]. The peptides and proteins isolated from *M. meretrix* exhibited potential antihypertensive as well as antineoplastic effects ([@b2140]). A sulfated *N*-acetylglucosamino glucuronopyranosyl-arabinopyranan isolated from seafood *Amphioctopus neglectus* displayed potential angiotensin converting enzyme attenuation properties. This sulfated polysaccharide was reported to attenuate angiotensin-II induced cardiac hypertrophy of the cardiomyoblast cells ([@b0400]).

8.4. Antidiabetic activity {#s0115}
--------------------------

Previous reports of literature described that the antidiabetic potencies of the cephalopod molluscs were greater than those exhibited by the gastropods and bivalves ([@b2000]). Potent antidiabetic effect of *C. indicus* extract was particularly due to its dipeptidyl peptidase-IV inhibitory property ([@b0460]). Organic extract of *C. indicus* inhibited the degradation of glucose-dependent insulinotropic polypeptide and glucagon-like peptides (incretins) to enhance the generation, and the release of insulin from pancreatic *β*-cells ([@b1220]). Therefore, it is of note that the inhibition of dipeptidyl peptidase-IV was important for the effective maintaining of serum glucose levels, and thus the activities of endogenous incretins were preserved ([@b1220]). The bivalve clams, *P. malabarica* and *V. cyprinoides* exhibited *in vitro* anti-diabetic potentials against the carbolytic enzymes, and dipeptidyl peptidase-IV with IC~50~ (inhibitory concentration at 50 % inhibition) values of 1.39-1.54 and ∼1.04 mg/mL, respectively ([@b1165]). Methanol extract of *Cerithidea obtuse* (snail) was composed of alkaloids, terpenoids, and flavonoids with potential antidiabetic property (IC~50~ value of 36.40 mg/mL) ([@b0305]). An isochromenyl derivative isolated from *S. inermis* exhibited efficient inhibition of carbolytic (IC~50~ 0.19-0.27 mg/mL) and dipeptidyl peptidase-IV enzymes (IC~50~ 0.16 mg/mL) ([@b1260]). An antioxidant 1*H*-benzochromenone reported from *C. ramosus* displayed greater inhibitory activity against the carbolytic enzymes (IC~50~ ∼0.72 mM) when compared to the antidiabetic drug, acarbose (IC~50~ 0.43 mM) ([@b0385], [@b0380]).

8.5. Antimicrobial activity {#s0120}
---------------------------

Marine and estuarine molluscs were identified as untapped resources of several antimicrobial compounds, including indole alkaloids, chlorinated acetylenes, peptides, and glycol proteins ([@b2265]). Among these, antimicrobial peptides were shown to be an important class of host defensive system of many molluscs, and the presence of polysaccharides, especially sulfated muco-polysaccharides were also attributed to their antimicrobial potentials ([@b0730]). These species used their innate immunity to get along with the invading microbial pathogens due to the lack of a well-defined defensive system. To date, an approximate number of 69 peptides with antimicrobial properties were described from the bivalves and gastropods ([@b1295]). Antimicrobial activity was reported from the mucus of giant snail  *Achatina fulica*, in which the highest potency was reported against  *Escherichia coli*, and the lowest against  *Klebsiella oxytoca* ([@b0730], [@b1270]). Crude ethanol extract of gastropod, *B. spirata* exhibited pronounced antimicrobial property against wide range of bacterial and fungal strains ([@b1635]). It was reported that the steroids extracted from mollusc, *M. meretrix* displayed potential inhibition of cell growth, along with induction of G1-phase cell cycle arrest in the hepatoma cells ([@b2200]). Bactericidal proteins from the Littoral mollusc *Cenchritis muricatus* with antibacterial property was reported previously ([@b1305]). Protein extract from the gastropod, *Cryptozona bistrialis* was found to be capable of inhibiting various pathogenic microorganisms ([@b2040]). [@b0070] described the antifungal activity of polyproline-type antimicrobial peptides (47 residues) from the Chilean scallop, *Argopecten purpuratus* against *Fusarium oxisporum*  and  *Saprolegnia parasitic.* Hemocyanins isolated frthe om hemolymph of *H. aspersa* showed prospective antimicrobial properties against Gram-positive pathogen *Streptococcus epidermidis* and Gram-negative *E. coli* ([@b0730]). Antibacterial and antifungal potentials of *B. spirata*, *P. glaucum*, *T. dolium*, *Hemifusus pugilinus*, *C. ramosus* and *B. zeylanica* collected from the southeast coast of India were investigated previously ([@b0995]). The abalone exhibited *in vitro* and *in vivo* antibacterial properties ([@b2095]). Antimicrobial activities of gill extract from the bivalve, *P. viridis* ([@b0485]) and crude solvent fractions of marine clam, *Anadara granosa* and *M. casta* against pathogenic bacteria were reported ([@b1700], [@b1705]). Previous and on-going investigations disclosed that the mollusc species of marine and estuarine origin were not only an important source of food, but are also promising candidates for development of antibiotic drugs against bacterial and fungal infections.

8.6. Antiviral activity {#s0125}
-----------------------

Marine molluscs were economically viable sources of antiviral compounds due to their extensive ability to fight against viral infections ([@b1205]). This was due to the absence of a well-defined adaptive immune system, and these species make use of their inherent immune system as a defense against viral infections ([@b1205]). Antiviral properties of the marine and estuarine molluscs were attributed to RNA interference, programmed cell death responses, and similar to the vertebrate interferon pathway ([@b1000]). Peptides and glycoproteins extracted from the molluscs were the predominant compounds responsible for their antiviral properties ([@b1270]). Kelletinin A isolated from *Buccinulum corneum* showed potency against the human T-cell leukemia virus type 1 ([@b1585]). Defensin and mytilin isolated from *M. galloprovincialis* possessed activity against human immunodeficiency virus type-1 (HIV-1) and white spot syndrome virus, respectively (Dupuy & Bonami, 2004; [@b1735]). A lectin derived from *Crenomytilus grayanus*s showed activity against HIV ([@b1315]). These compounds were found to interact with the invading virus, and prevent their binding with target cells or inhibit its replication and transcription ([@b1315]). Hemocyanin 1 and 2 (glycosylated functional part) extracted from *Rapana thomasiana* exhibited antiviral activity against both herpes simplex virus type-1 and Epstein-Barr virus by inhibiting the replication at 200 μg/mL and 1 μg/mL, respectively ([@b0520]). The abalone eas reported to possess antiviral properties against human pathogens, as described by the *in vitro/in vivo* experiments on the infected mice ([@b1290]). Extracts from *P. viridis*, *C. madrasensis*, *C. gryphoides*, *M. casta*, *V. cyprinoides*, and *Polymesoda erosa* were found to possess prospective antiviral activities against influenza virus type-A and type-B ([@b0495]). In addition, *P. viridis* was reported for its antimicrobial, radioprotective, antiangiogenic and anti-HIV potencies ([@b0050], [@b1465]). The sea hares, *Dolabella*, *Bursatella* and *Aplysia* were found to be the potential sources of anti-HIV metabolites ([@b2225]). A new polysaccharide bearing galactansulfate isolated from the clam, *Meretrix petechialis* exhibited anti-HIV activity ([@b0030]).

8.7. Anticancer activity {#s0130}
------------------------

Chemical investigation of molluscan phylum described various compounds as potential anticancer drugs based on their ability to overcome the cancer cell resistance chemotherapy ([@b0555]). The reason behind the selection of mollusc-derived anticancer drug candidates were due to their ability to target the biological characteristics of cancer cells, and their potency, selectivity, mechanisms of action along with alimentary behaviour ([@b0555]). Now-a-days, researchers are focused in the identification of peptides as caspase activators, since these were involved in the intracellular and extracellular apoptosis pathways ([@b2260]). For example, dolastatin-10 derived from *D. auriculata*, and its synthetic analogs were currently passed through phase-II clinical trials, as antitumor agents ([@b1330]). Kahalides showed both *in vitro/in vivo* activities against cancer cells through the inhibition of lysosomal function leading to the cell death ([@b1925]). Molluscan peptides were found to possess anticancer properties through different mechanisms of action in killing the cancer cells, like inhibition of angiogenesis, apoptosis, and disruption of tubulin-microtubule balance ([@b1190]). Enzymatic hydrolysate of jumbo squid skin gelatin was found to exhibit cytotoxicity against MCF-7 and U-87 cell lines with IC~50~ values of 0.13 and 0.10 mg/mL, respectively ([@b0500]). The cephalopod species, *Paraoctopus limaculatus* (octopus) was studied for their antimutagenic and antiproliferative effects ([@b1495]). Various antitumor metabolites were isolated from the squid ([@b0500]), octopus ([@b1195]), and cuttlefish ([@b1845]). Extract of edible clam, *Mercenaria mercenaria* was found to attenuate the development of tumors in the Swiss mice ([@b1830]).

8.8. Other pharmacological activities {#s0135}
-------------------------------------

The gastropod snail, abalone was recommended for physically weak patients ([@b1225]). Studies on bioactive properties of mucus from *Helix sp.* revealed its mucolytic, bacteriolytic, antispasmodic properties ([@b0265]). Anticoagulant properties of abalone extracts were studied previously ([@b1225]). Conopeptides from the cone snails were reported for various biomedical pluralities, such as antinoceptive, analgesic, and as neuroprotectives (Han, Teichert, & Olivera, 2008; [@b2025]). Recent pharmacological studies on secretions of *C. aspersa* were described for their skin regenerative pluralities through anti-oxidant activity, stimulation of fibroblast proliferation along with metalloproteinase regulation potencies ([@b0290]). The cephalopods including squid and octopus have broad physiological actions, such as immune and anti-inflammatory responses, along with neural function and reproduction ([@b1460]). A natural thrombolytic agent, C-type hemolytic lectin was purified from *V. cyprinoides* with activity against myocardial infarction ([@b1935]). Asiatic hard clam, *M. meretrix* was reported to exhibit several pharmacological activities, such as immunomodulatory, anti-hyperglycemia, and anti-hyperlipidemia along with detoxification effects ([@b2210]). Hard protective shell of Onchidiacea mollusc species secreted viscous fluid that could prevent it from predation. The lipid soluble extract, Onchidal^TM^ was found to be the major product of *Onchidella binneyi* that could inhibit the activity of acetylcholinesterase enzyme in an irreversible pattern ([@b1485]). Turbotoxin A from *Turbo marmorata* (gastropod) was active against acetylcholinesterase enzyme (IC~50~ 28 mM), and the compound was not found to interfere with the peripheral nervous system ([@b1485]). Acetylcholinesterase inhibition activity was previously reported for the oyster, *Crassostrea virginica* ([@b0260]). The clam, *M. meretrix* displayed hypolipidemic pluralities ([@b2140]). Potent anti-hypercholesterolemic (IC~90~ 1.21 mg/mL) property of *A. marginatus* attributed its utilities as natural sources of bioactives in food supplements and nutraceuticals ([@b1250]).

9. Molluscan pharmaceuticals: a modern pipeline perspective {#s0140}
===========================================================

Natural products from the marine and estuarine molluscs were regarded as the backbone of modern therapeutics and pharmaceuticals. Recently, wide-range of bioactive natural products isolated from the molluscs were used in the formulation of pharmaceutical drugs ([Table 6](#t0030){ref-type="table"} ; [Fig. 5](#f0025){ref-type="fig"}) ([@b1875]). The molluscan derived drug, ziconotide was approved by the Food and Drug Administration (FDA) ([@b1420]). Cytarabine and vidarabine were the first two marine natural products, which were added into the "pharmacopoeia" in 1974, for treating the human diseases. Following that, it has been taken through 30 years, for the identification and approval of the mollusc derived ziconotide, and it was added to the "pharmacopeia" in 2004 ([@b1420], [@b1680]). Dolastatin-10 and its synthetic analogs from *D. auriculata* were under phase-II clinical trials as anticancer agents ([@b1330]). Kahalalide F identified from *Elysia rufescens* ([@b1305]), and ES-285 from bivalve, *Mactromeris polynyma* completed the phase-I clinical trials ([@b0705], [@b0755]). Some important pharmaceuticals of molluscan origin with various therapeutic potentials were described below.Table 6The current pipeline of pharmaceuticals from molluscs.**Clinical statusCompound name and structureStudied molluscTrademarkCompound classInstitution/CompanyDisease area**Approved by FDAZiconotide[a](#tblfn7){ref-type="table-fn"}![](fx1_lrg.gif)*Conus magus* (snail)PrialtPeptideElan CorporationAIDS or cancerPhase II trialsElisidepsin^b^![](fx2_lrg.gif)*Elysia rufescens* (slug)IrvalecDepsipeptidePharmamar companyCancerPhase II trialsDolastatin 10^c^![](fx3_lrg.gif)*Dolabella auricularia*(Sea hare)NAPeptideCelltrion pharmaceutical companyCancerPhase II trialsTasidotin-HCl^d^ (ILX-651)![](fx4_lrg.gif)*Dolabella auricularia*,Dolastatin-15 analogueNADepsipeptideNACancerPhase I trialsSpisulosine^e^![](fx5_lrg.gif)*Spisula polynyma* (surf clam)NAAmino alcoholPharmamar GroupCancerPhase I trialsCematodin-HCl (LU-103793)^d^![](fx6_lrg.gif)*Dolabella auricularia*,Dolastatin-15 analogueNAPentapeptideNACancerPhase I trialsZalypsis^f^![](fx7_lrg.gif)*Jorunna funebris*(slug)ZalypsisAlkaloidPharmamar companyCancerPhase I trialsTZT-1027^g^![](fx8_lrg.gif)*Dolabella auricularia*,Dolastatin-10 analogueNAPeptideNAAnti-vascular[^10]

9.1. Ziconotide (Prialt) {#s0145}
------------------------

A synthetic equivalent of 25-amino acid peptide, *ω*-conotoxin MVIIA was initially isolated from the venom of *Conus magus* ([@b0160]). It is an effective analgesic with novel mechanism of action ([@b0160]). Different subtypes of voltage-gated calcium channels were identified in the nervous system. Ziconotide could reversibly block the *N*-type calcium channels situated on the primary nociceptive afferent nerves in superficial layers of dorsal horn of spinal cord. Binding of ziconotide to the presynaptic *N*-type calcium channels could reduce the generation of excitatory neurotransmitters from primary afferent nerves ([@b1440]). In the opiate-based therapies, the tolerance levels to drugs were found to be the major limiting factor, whereas ziconotide did not produce any tolerance levels ([@b1440]). Detailed experiments found the inability of ziconotide to cross blood-brain-barrier, and could be delivered into the spinal theca using implantable pump or temporarily by external microinfusion device ([@b1440]). It was accredited by the FDA in December 2004, and presently labeled for management of chronic pain in patients with AIDS or cancer ([@b1715]). Prialt® was commercialized by Elan Corporation, PLC (retrieved from http://www.elan.com/therapies/products/prialt.asp), and ziconotide was approved to market in the Europe, Middle East and Africa ([@b2190]).

9.2. Elisidepsin (Irvalec, PM02734) {#s0150}
-----------------------------------

It is cyclic a depsipeptide belonging to dehydroaminobutyric acid containing peptide family of compounds, called as kahalalides, which were isolated from the herbivorous mollusc, *E. rufescens* ([@b1305]). The pharmacophore agent successfully completed phase-II clinical trials with antitumor activities in the wide variety of cancer cells, including lung, breast, pancreas, colon, and prostate. Its primary mechanism of action is yet to be elucidated, even though it was reported that this compound could induce oncolytic rather than apoptotic cell death. It inhibited the expression of certain genes involved in the DNA replication, and cell proliferation, and thus, it inhibited the tumor spreading and growth ([@b1420]). Elisidepsin^TM^ is being developed by Pharmamar (PM02734) (http://www.pharmamar.com/products.aspx).

9.3. Zalypsis (PM00104) {#s0155}
-----------------------

It is a DNA-binding alkaloid similar to jorumycin isolated from the mucus, and skin of the Pacific nudibranch mollusc, *Joruna funebris* ([@b1835]). It was found to bind the guanines in the selected DNA triplets, and then the DNA adducts gradually could give rise to the double-strand breaks, S-phase arrest, and finally apoptosis in the cancer cells. The preclinical *in vivo* studies described its potent antitumor activities in the prostate, renal, breast and colon cancer (http://www.pharmamar.com/products.aspx), and the alkaloid is currently under its phase-II clinical trials.

9.4. Dolastatins {#s0160}
----------------

These were cyclic or linear peptides identified from the marine mollusc,  *D. auricularia*. Among the dolastatins, dolastatin-10 and 15 displayed promising antiproliferative action ([@b1665]). Dolastatin-10 was the most potent antiproliferative dolastatin, and was found as a linear pentapeptide with several significant amino acid residues. Dolastatin-10 was selected for the clinical trials due to the favorable preclinical advantages, and was under phase-II clinical trials as anticancer drug ([@b1665]). Its mode of actions involves the inhibition of microtubule assembly, and tubulin polymerization followed bythe cells arrest in the metaphase ([@b1615]). Lesser synthetic yield and water solubility along with the structural complexity of dolastatins were the barriers for their wider clinical evaluations ([@b1665]). Synthetically, various analogs of dolastatin-10 were prepared, among these the drug named as TZT-1027 with antivascular activity was identified. TZT-1027 was found to possess *in vivo* antiangiogenic activity in the chorioallantoic membrane embryo, and human umbilical vein endothelial cells. However, it didn't exhibit anticancer activity in phase-II clinical trials ([@b1725]). Dolastatin-15 obtained from  *D. auricularia*  was not clinically investigated, but its water-soluble derivatives named as LU-103793 (cematodin) and ILX651 (tasidotin) were formulated as anticancer drugs for the clinical studies ([@b1190]). In this, LU-103793 could complete the phase-I clinical trial for curing of cancer, but the phase-II trial was interrupted. ILX-651 could complete the phase-I clinical trial, and the phase-II trial was suggested due to no cardiotoxicities. Tasidotin^TM^ has completed the phase-II trials against breast, prostate cancers and melanoma ([@b1190]).

9.5. Keenamide A {#s0165}
----------------

It is a cyclic hexapeptide isolated from the mollusc *Pleurobranchus forskalii*, and exhibited antitumor activities against the cancer cell lines, like MEL-20, A-549, P-388, and HT29 through unidentified mechanisms ([@b2155]).

9.6. Kulokekahilide-2 {#s0170}
---------------------

The cyclic depsipeptide, kulokekahilide-2 was a potent aurilide-type of compound, which was firstly isolated from *Philinopsis speciose*. Structural similarities with aurilides confirmed that it was biosynthesized by the marine cyanobacteria, and it exhibited anticancer activities against various cell lines, such as P388, SKOV-3, MDA-MB-435 and A-10 ([@b1515]).

9.7. Spisulosine ES-285 {#s0175}
-----------------------

The compound was found to be a potent antiproliferative alkyl amino alcoholic compound, and was identified from *Spisula polynyma* by the Spanish Pharmamar group. Spisulosine exhibited an intriguing mechanism of action, and the molecular target of this molluscan alkyl group was found to be Rho (GTP-bp). The compound was undergoing phase-I clinical trials as an antiproliferative agent (Cuadros, Garcini, Wandosell, Faircloth, & Sousa, & Avila, 2000).

10. Publications in the subject of high value compounds from molluscs: The trends from the past {#s0180}
===============================================================================================

The annual reviews of marine natural products (MNPs), inclusive of the phylum Mollusca were initiated by late Professor D. John Faulkner in 1984, and was continued by the New Zealand group from 2003 till 2019. These reviews included the structures of new secondary metabolites and their revisions. The increased numbers of publications with respect to the marine molluscan natural products described the significance of the organisms. The natural product reports on "marine natural products" of molluscan origin described more than 604 publications between 1984 to 2002 ([@b0770], [@b0775], [@b0780], [@b0785], [@b0790], [@b0795], [@b0800], [@b0805], [@b0810], [@b0815], [@b0820], [@b0825], [@b0830], [@b0835]), and more than 683 publications between the period spanning between 2003 to 2019 ([@b0215], [@b0220], [@b0225], [@b0230]; 2007; 2008; 2009; 2010; 2011; 2012; 2013; 2015; 2016; 2017; 2018; [@b0355]) ([Fig. 6](#f0030){ref-type="fig"}). Benkendorff ([@b0125]) described 146, 11, and 878 published reports on the pharmaceutical effects of bivalves, cephalopods, and gastropods, respectively. The database of marine natural product literature, MarinLit described a total of 2456 publications by using the keywords "molluscs or molluscan" (MarinLit, accessed on 01/10/2019). A recent search in Sci-Finder, using the keywords "bivalves" retrieved 12594 publications, whereas the keyword "cephalopods" retrieved 1724 publications, and that of "gastropods" retrieved 4941 publications (Sci-Finder, accessed on 15/09/2019). Search in PubMed using the molluscan derived drugs, such as "*ω*-conotoxin MVIIA, SNX-111, ziconotide or prialt" recovered 60521 publications in the peer-reviewed literatures (PubMed, accessed on 20/09/2019). Similarly, another drug "elisidepsin or kahalalides" search in PubMed retrieved a total of 35 publications (PubMed, accessed on 21/09/2019). The keywords, "zalypsis or jorumycin" were described by 34 publications, and the search terms like, "dolastatins, dolastatin 10, dolastatin 15, LU-103793, cematodin, ILX651 or synthadotin" described 15 publications in the PubMed (PubMed, accessed on 22/09/2019). The keyword "keenamide A" retrieved 2 publications, whereas the "kulokekahilide-2 or aurilide" retrieved 11 publications, and "spisulosine ES-285" was reported by a total number of 32 publications in the PubMed search (PubMed, accessed on 24/09/2019). A recent search was carried out on the pharmacological activities, such as "antioxidant, anti-inflammatory, antihypertensive, antidiabetic, antimicrobial, antiviral and anticancer" effects of some selected molluscan species (*H. diversicolor*, *H. discus*, *B. spirata*, *B. zeylanica*, *B. spinosa*, *C. ramosus*, *P. malabarica*, *V. cyprinoides*, *M. meretrix*, *P. viridis*, *P. canaliculus*, *C. madrasensis*, *L. duvauceli*, *C. indicus*, *S. pharaonis*, *S. inermis*, *A. marginatus*) in Google Scholar (accessed on 13/10/2019). It was described that, around 23 % of publications were related to the pharmacological activities of *H. discus* followed by *P. viridis* (20 %), *M. meretrix* (15 %) and *H. diversicolor* (12 %). The emerging trends in the numbers of publications in the field of molluscan research, particularly in the pharmacological effects of molluscs attracted the attention of marine natural product chemists and medical researchers to focus on this diverse phylum.

11. Emerging trends in patents from the marine and estuarine molluscs {#s0185}
=====================================================================

The numbers of granted patents in the field of mollucsan research were found to be increased in the recent years. Comparative study of the granted patents in this area from 1985 to 2019 were carried out, which includes the cultivation, harvesting, preservation of molluscs, along with its therapeutic and nutraceutical utilities (retrived from Google patents as on 12/10/2019) ([Fig. 14](#f0070){ref-type="fig"} ). The numbers of granted patents were found to be 2 % in between the years of 1985 to 1990, and which was increased to more than 30 % during 2016-2019. Herein, we have only reviewed the patents related to the pharmaceutical and nutraceutical applications of the molluscs ([Table 7](#t0035){ref-type="table"} ). The powder of abalone shell was incorporated into a patented formula for treating burns without pain and scaring ([@b1285]). Lyprinol®, the lipid extract of *P. canaliculus* was patented for arthritis and asthma with proven range of clinical trials ([@b0960], [@b1015]). Lyprinol® was found to be effective in the prevention of inflammatory bowel disease ([@b1985]), and the therapeutics including the extracts of *P. canaliculus* were patented for use in the treatment of side effects of analgesics caused in the gastro-intestinal tracts ([@b1435]). Commercialized nutraceutical supplement, Cadalmin^TM^ green mussel extract containing 100% natural marine bioactive anti-inflammatory ingredients extracted from the Asian green mussel *P. viridis* for use against rhumatoid arthritis pain was patented ([@b0425]; [@b0430])*.* Active principles in Cadalmin^TM^ green mussel extract displayed potential capacities to attenuate experimentally induced inflammation, and can act as dual inhibitors of 5-lipoxygenase and cyclooxygenase-2 pathways, thereby down-regulating the biosynthesis of inflammatory leukotrienes and prostaglandins. Mean lethal dose (LD~50~) of the product was greater than 4000 mg/kg body weight of the animal subjects that indicate the safety of the product (Chakraborty, Joseph, & Chakkalakal, 2014b). Cosmetic cream made from the mineral or organic phases of mother of pearl, *Pinctada maxima* was patented for its dermatological functions (skin regeneration process) and wound healing properties ([@b0315]). The patent document, WO2006122296 described the identification of four novel cerebroside compounds, named as turbostatin 1-4 from the marine mollusc, *Turbo stenogyrus*. These compounds exhibited significant cancer cell growth inhibition against murine and human cancer cells, and were found to be useful against various neoplastic ailments ([@b1640]).Fig. 14Comparison of granted patents from 1985 to 2019 in the area of molluscan research (retrived from Google patents, accessed on 12/10/2019).Table 7Examples of pharmaceuticals or nutraceutical patents reported from molluscan species**Studied molluscPatent numberDescription of the inventionReferences***Pinctada maxima*US5773034Cutaneous rejuvenating, healing, dermatological purposes, skin problems[@b0315].*Perna canaliculus*US4455298Pharmaceutical preparations with gastroprotective action, antiulcer potentials[@b1435]*Perna viridis*IP302803 (Application number-2065/CHE/2010)The process to concentrate anti-inflammatory principles[@b0425]*Perna viridis*IP303813 (Application number-2066/CHE/2010)Anti-inflammatory product against pro-inflammatory enzymes[@b0430]*Turbo stenogyrus*WO2006122296Isolation and structure of turbostatins 1-4, inhibition activity against cancer cell growth, inhibition of several murine and human cancer cell lines, useful in the treatment of various neoplastic diseases[@b1640]*Elysia rufescens*US20040067895A1Kahalalide F formulation, potent against *in vitro* human lung carcinoma A-49 and human colon carcinoma HT-29[@b1560]*Elysia rufescens*PL356800A1Kahalalide compounds, potent against pathogenic microorganisms which cause the opportunistic infection of HIV/AIDSAlbericio et al., 2004*Mytilus edulisMytilus galloprovincialis*DE4309339A1Biologically active pharmaceutical product, prophylactic and therapeutic radiopharmaceutical functions in humans and animals, antiinflammatory effects, blood production, stimulates regeneration processes after injuries and operations, effective against psychological or physical stress[@b1275]*Perna viridis*US6905710B2Pharmaceutical composition useful for inhibition of osteoclast formation, inhibition of osteoclast formation[@b2115]*Perna canaliculusMytilus edulis*WO2006128244A1The enzyme assisted mussel oils all exhibited significant inhibition of mammalian cyclooxygenases 1 and 2, antiinflammatoryactivity[@b1325]*Telescopium telescopium*IN2007KO00858ABioactive compounds, potential anticancer or antiproliferative agent[@b1760]*Mytilus galloprovincialis*WO2001004294A1Peptides derived from molluscs, antimicrobial activity[@b1730]AbaloneEP2280726A1Nutraceutical, used in prophylaxis of viral infection in mammal, anti-viral agent[@b0655]

Bivalve mussels belonging to the class Mytillidae were recently subjected to several patents as prospective sources of antimicrobial ([@b0695]) and antiviral ([@b0150], [@b1745]) peptides. An anti-HIV formulation with application number 60/280,086, from the Indian green mussel, *P. viridis* was patented (Patent Number US6770302B2/en) ([@b1050]). The anticancer agent, kahalalide F isolated from *E. rufescens* was patented for anticancer activities against colon, breast, ovarian, and lung cancer, and particularly against androgen-independent prostate cancer (Patent Number US 2004067895A1) ([@b0755], [@b1305], [@b1560]). The compound was also active against the pathogenic microorganisms, such as HIV or AIDS, and was currently undergoing phase-II clinical trials in Europe ([@b0020]). Acid hydrolyzates of *M. edulis* and *M. galloprovincialis* were patented for the use as a prophylactic, antipyretic, and as a therapeutic radiopharmaceutical medication ([@b1275]). Methods of cancer treatments using the bivalve, *P. canaliculus* was patented (application number 60/454,340). Production of protein hydrolysate from the zebra mussel as food products, medical-prophylactics, and its use in medical, microbiology, and veterinary organizations were patented ([@b2115]). Pharmaceutical composition of the mussel hydrolysate of *P. viridis* was formulated and patented for the inhibition of osteoclast formation, and these compositions were found to be non-toxic to other cells ([@b2130]). Trachyostracous mussel extract was patented for the use in the preparations of anti-SARS (anti-severe acute respiratory syndrome), anti-influenza, and immunomodulatory drugs (Chinese patent number CN100467030C, 2009). An antioxidative composition of the peptide isolated from the protein hydrolysate of *M. coruscus* as an active ingredient to prevent the process of ageing was patented (Korean patent number KR20120049042A, 2012).

12. Biotoxins from molluscs: Potential candidates for the development of pharmacophores {#s0190}
=======================================================================================

Majority of the molluscan species significantly contributed towards the health benefits, nutritional aspcets, and economic developments. Even though, the human intoxication was reported by the consumption of molluscs due to the production of biotoxins as part of their defence mechanisms. According to the chemical structure, the biotoxin were classified as azaspiracid, brevetoxin, okadaic acid, pectenotoxin, saxitoxin, cyclic imine and yessotoxin. These biotoxins were attracted the attention of researchers owing to their potent biological activities, and as candidates for drug developments and biological probes for physiological analyses ([@b2035]). Important shellfish poisoning were classified as amnesic shellfish poisoning (ASP), diarrhetic shellfish poisoning (DSP), neurotoxic shellfish poisoning (NSP), and paralytic shellfish poisoning (PSP), ([Table 8](#t0040){ref-type="table"} ). Cyclic polyether derivatives, such as brevetoxins could pass through the cell membranes, and interact with neurotransmitter receptors resulting in neurotoxicity and various neurological disorders ([@b1095]). Brevetoxin B5 was reported from *Austrovenus stutchburyi* (cockle), *C. gigas* and *P. canaliculus* ([@b1500]), and brevetoxin B2 was isolated from *P. canaliculus* (Ciminiello et al., 2007a). Okadaic acid and dinophysistoxins were found to inhibit the protein phosphatases, and resulted in diarrheagenicity and neurotoxicity. Oxazinin and its derivatives were reported from *M. galloprovincialis*, and were found to be responsible for DSP poisoning ([@b0605]; Ciminiello et al., 2007b). Saxitoxins were reported from *Saxidomus giganteus* (Wiese, D\'Agostino, Mihali, Moffitt, & Neilan, 2010), *Mytilus chilensis* and *Tagelus dombeii*, and were found to be responsible for paralytic poisoning ([@b1990]). The molluscs, such as *M. edulis*, *Siliqua patula*, *Mya arenaria* and *P. magellanicus* were reported for the production of domic acid, which could cause ASP poisoning (Farabegoli, Blanco, Rodriguez, Vieites, & Cabado, 2018). Another bivalve, *P. muricata* was reported for its acute toxicity in mice due to the production of pinnatoxins, pinnamine, and pinnaic acid ([@b1970]). The known spiroimine toxins, pinnatoxin A, and D, pinnatoxin E-G were isolated from the digestive glands of *C. gigas* ([@b1840]). Pinnatoxins and their fatty acid ester metabolites were identified from the mussel (*M. edulis*) ([@b1425]). Pectenotoxin-4 and 7 were purified from the Japanese scallop, *P. yessoensis* ([@b1825]). Even though there were incidences of mollusc biotoxins, these compounds were of interest for marine natural product chemists to develop several life-saving drugs.Table 8Classification of molluscan biotoxins and their main side effects in humans**Molluscan biotoxinsSourceSymptomologyParalytic shellfish poisoning (PSP)**![](fx9_lrg.gif)Saxitoxin*Alexandrium* *spp., Pyrodinium bahamense*Gastrointestinal problems, Paralytic problems, Recovery or death**Neurotoxic shellfish poisoning (NSP)**![](fx10_lrg.gif)Brevetoxin B5![](fx11_lrg.gif)Brevetoxin B2*Karenia brevis*Gastrointestinal, neurological respiratory, problems**Diarrhetic shellfish poisoning (DSP)**![](fx12_lrg.gif)Yessotoxinanalogue, adriatoxin![](fx13_lrg.gif)Desulfoyessotoxin*Protoceratium reticulatum, Gonyaulax spinifera*Lack of observations in humans![](fx14_lrg.gif)![](fx15_lrg.gif)Oxazinins-Gastric problems**Miscellaneous**![](fx16_lrg.gif)Azaspiracid*Amphidoma languida Azadinium spinosum*Gastrointestinal symptoms![](fx17_lrg.gif)Pectenotoxin*Dinophysis spp*.Gastrointestinal problems

13. Molluscs: Future aspects and conclusion {#s0195}
===========================================

Till date, only a small proportion of the molluscan species was used towards the isolation and characterization of novel bioactive secondary metabolites. The knowledge of existing ethnopharmacological utilities of molluscs could lead to greater developments and formulations in healthcare as well as therapeutic interest. Preliminary data of traditional medicines and bioactive potentials were predominantly obtained from the bivalves, cephalopods and gastropods appropriately suggested the potential utilities of these species, when compared to other classes of this phylum. Commercial significance of the molluscs suggested that these could be regarded as valuable fishery resources in various parts of coastal regions of the world. The nutritive and health benefits of the molluscs suggested that these could be added to our daily diets to improve the health benefits and the enhancement of the immune systems. This review revealed that the marine and estuarine molluscs could be utilized as valuable bioresources to develop new therapeutic and high-value constituents with wide-range of pharmacological activities. The percentage of granted patents from 2016 to 2019 in the area of molluscan research was increased to more than 30 %, which recognized the significance of the molluscan phylum to develop high value compounds of pharmaceutical significance. Notably, more than 1334 secondary metabolites with potent bioactive properties were isolated and identified from the marine molluscs between the periods of 1984 to 2017. In particular, the studies on scaphopoda and polyplacophora class of molluscs would be regarded as valuable for further studies due to their availability and reasonably larger size, along with the knowledge of their traditional uses. Due to the promising pharmacological profiles of the molluscs, further studies are warranted to develop medications and nutraceutical products to alleviate several life-thretening ailments. The bioactive compounds from the molluscs of marine and estuarine origin could also be utilized in the development of potential therapeutic templates and functional food products.
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